| Excerpt | Reference |
|---|
| "Fifteen cases of perineal neuralgia are reviewed, the lesion arising from a canal syndrome due to compression of the pudendal nerve in the ischiorectal fossa (Alcock's canal syndrome)." | ( Amarenco, G; Ghnassia, RT; Goudal, H; Lanoe, Y; Perrigot, M, 1988) |
| "Diagnosis of neuropathic pain is often easily made from information gathered on neurologic examination and from patient history." | ( Galer, BS, 1995) |
| "Neuropathic pain is poorly managed by conventional analgesic therapy, such as non-steroidal anti-inflammatory drugs and opiates." | ( Campbell, EA; Gentry, CT; Panesar, MS; Patel, S; Urban, L; Walpole, CS, 1998) |
| "Neuropathic pain is frequently associated with hyperexcitability of primary afferents, characterized by spontaneous impulses and repetitive firing." | ( Khodorova, A; Sinnott, C; Strichartz, GR; Zhou, Z, 2002) |
| "Neuropathic pain is a common complaint after traumatic spinal cord injury (SCI)." | ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Neuropathic pain is a common and often incapacitating clinical problem for which little useful therapy is presently available." | ( Brown, SM; Butler, MP; Chaplan, SR; Dubin, AE; Guo, HQ; Kuei, C; Lee, DH; Liu, C; Luo, L; Velumian, AA, 2003) |
| "Neuropathic pain is often severe and resistant to pharmacological treatment." | ( Emanuelsson, BM; Gordh, T; Karlsten, R; Kvarnström, A; Quiding, H, 2003) |
| "Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system." | ( Levendoglu, F; Ogün, CO; Ogün, TC; Ozerbil, O; Ugurlu, H, 2004) |
| "Rodent models of neuropathic pain are used to investigate the underlying mechanisms of pain associated with damage to peripheral nerves and to evaluate the efficacy of novel compounds." | ( LaBuda, CJ; Little, PJ, 2005) |
| "Neuropathic pain is associated with numerous systemic illnesses, including HIV infection." | ( Estanislao, L; Mintz, L; Simpson, D; Verma, S, 2004) |
| "Treatment of neuropathic pain is an area of largely unmet medical need." | ( Caram-Salas, NL; Granados-Soto, V; Medina-Santillán, R; Reyes-García, G, 2006) |
| "Neuropathic pain is associated with a number of disease states of diverse aetiology that can share common pathophysiological mechanisms." | ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Integral to neuropathic pain is a reciprocal interaction between tumor necrosis factor-alpha (TNF) production and the alpha(2)-adrenergic receptor response, offering an attractive therapeutic target." | ( Ignatowski, TA; Lo, CP; Spengler, RN; Sud, R, 2007) |
| "Neuropathic pain is defined as pain caused by a lesion in the nervous system and is common in clinical practice." | ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Neuropathic pain is associated with several sensory abnormalities, including allodynia as well as spontaneous pain." | ( Buechler, NL; Eisenach, JC; Kim, SA; Martin, TJ; Porreca, F, 2007) |
| "Neuropathic pain is a type of chronic pain following central or peripheral nervous system lesions that cause allodynia (pain initiated by a non-painful stimulus) and hyperalgesia (increased pain sensation following a painful stimulus)." | ( Beaudry, F; Guénette, SA; Marier, JF; Ross, A; Vachon, P, 2007) |
| "Central neuropathic pain is a debilitating and frequent complication to spinal cord injury (SCI)." | ( Finnerup, NB; Jensen, TS; Johannesen, IL; Pedersen, LH; Terkelsen, AJ, 2007) |
| "Neuropathic pain is a personally devastating and costly condition affecting 3-8% of the population." | ( Coderre, TJ; Gilron, I, 2007) |
| "Peripheral neuropathic pain is a common clinical problem with few existing treatments." | ( Chang, JW; Kim, J; Kim, SJ; Lee, B; Lee, H, 2007) |
| "Neuropathic pain is the focus of much current research activity, particularly pharmacological research, and this chapter will attempt to identify gaps in our clinical knowledge and highlight opportunities for further research." | ( Abrahams, MJ, 2007) |
| "The treatment of neuropathic pain is challenging, in part because of its multiple etiologies." | ( Codd, EE; Martinez, RP; Molino, L; Rogers, KE; Stone, DJ; Tallarida, RJ, 2008) |
| "The treatment of neuropathic pain is a major unresolved medical challenge." | ( Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007) |
| "Neuropathic pain is a difficult state to treat, characterized by alterations in sensory processing that can include allodynia (touch-evoked pain)." | ( Bee, LA; Dickenson, AH; Matthews, EA; Stephens, GJ, 2007) |
| "Neuropathic pain is often a consequence of nerve injury through surgery, bone compression, diabetes or infection." | ( Inoue, K, 2007) |
| "Neuropathic pain is a frequent condition that can result from a variety of underlying conditions and is frequently chronic and difficult to treat." | ( Beydoun, A; Nasreddine, W, 2007) |
| "Central neuropathic pain is a painful condition, often severe, that occurs in a person who is already affected by an injury or disease of the brain or spinal cord." | ( Gray, P, 2007) |
| "Management of neuropathic pain is challenging." | ( Cella, D; Cleary, JF; Cleeland, C; Eappen, S; Moots, P; Regevik, N; Taylor, SG; von Gunten, CF, 2007) |
| "Neuropathic pain is a long-lasting clinical problem that is often refractory to medical management." | ( Cao, X; Cao, Z; He, X; Li, W; Liu, L; Liu, W; Liu, Z; Miao, L; Xiao, Z; Xue, L, 2008) |
| "The treatment of neuropathic pain is mainly based on antiepileptics, tricyclic antidepressants, and opiates." | ( Arnold, P; Deriaz, O; Gobelet, C; Kuntzer, T; Vuadens, P, 2008) |
| "Neuropathic pain is the most difficult type of pain to treat." | ( Gao, Y; Liang, S; Mu, S; Wan, F; Wang, Y; Xu, C; Zhang, A, 2008) |
| "Chronic neuropathic pain is a frequent, serious outcome of spinal cord injury (SCI) that is highly refractory to treatment." | ( Chen, Y; Oatway, MA; Weaver, LC, 2009) |
| "Neuropathic pain is commonly associated with affective disorders such as anxiety and depression." | ( Blackbeard, J; Pheby, T; Rice, AS; Segerdahl, AR; Wallace, VC, 2008) |
| "Neuropathic pain is a complex syndrome resulting from damage to the peripheral nervous system." | ( Feng, X; Hu, Y; Jia, H; Li, W; Liu, J; Xu, J; Zeng, Q, 2009) |
| "Chronic neuropathic pain is inadequately treated using current therapies, with less than half of patients achieving clinically significant pain relief (defined as more than 50% pain reduction)." | ( Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS, 2009) |
| "Neuropathic pain is a chronic disease resulting from dysfunction of the nervous system often due to peripheral nerve injury." | ( Ernfors, P; Lucas, G; Mattsson, JP; Oerther, S; Staaf, S, 2009) |
| "Neuropathic pain is characterized by a poor response to classic analgesics." | ( Curros-Criado, MM; Herrero, JF, 2009) |
| "Chronic neuropathic pain is underrecognized and undertreated, yet primary care physicians are uniquely placed on the frontlines of patient management, where they can play a pivotal role in treatment and prevention through diagnosis, therapy, follow-up, and referral." | ( Backonja, MM; Baron, R; Bennett, MI; Bouhassira, D; Cruccu, G; Haanpää, ML; Hansson, PT; Jensen, TS; Kauppila, T; Rice, AS; Smith, BH; Treede, RD, 2009) |
| "Treatment of neuropathic pain is also specific, based on certain antidepressant or antiepileptic, often in combination with strong opioids." | ( Guastella, V; Mick, G, 2009) |
| "Treatment of neuropathic pain is a major clinical challenge that has been met with minimal success." | ( Asiedu, M; Kaila, K; Ossipov, MH; Price, TJ, 2010) |
| "Neuropathic pain is a debilitating pain that occurs after nerve injury and is generally resistant to currently available treatments including morphine." | ( Inoue, K, 2009) |
| "Neuropathic pain is a common problem in clinical practice, affecting patients physically, emotionally, financially, and socially." | ( Moradimehr, A; Shah, TH, 2010) |
| "Neuropathic pain is relatively uncommon in children." | ( Dworkin, RH; Krane, EJ; LeBel, AA; Treede, RD; Walco, GA, 2010) |
| "Neuropathic pain is caused by lesion or dysfunction of the peripheral sensory nervous system." | ( Bauer, CS; Dickenson, AH; Dolphin, AC; Lujan, R; Rahman, W; Tran-van-Minh, A, 2010) |
| "Models of neuropathic pain are associated with elevated spinal levels of endocannabinoids (ECs) and altered expression of cannabinoid receptors on primary sensory afferents and post-synaptic cells in the spinal cord." | ( Barrett, DA; Chapman, V; de Lago, E; Fernández-Ruiz, J; Gray, RA; Jhaveri, MD; Kendall, DA; Richardson, D; Sagar, DR, 2010) |
| "Neuropathic pain is a debilitating consequence of nerve injuries and is frequently resistant to classical therapies." | ( Brack, A; Labuz, D; Machelska, H; Schmidt, Y; Schreiter, A, 2010) |
| "Neuropathic pain is an intractable clinical problem." | ( Chen, L; Li, YQ; Mei, XP; Wang, W; Wu, SX; Xu, LX; Zhang, T; Zhu, C, 2010) |
| "Neuropathic pain is a common diabetic complication affecting 8-16% of diabetic patients." | ( Courteix, C; Daulhac, L; Davin, N; Eschalier, A; Fialip, J; Mazur, A; Privat, AM; Rondón, LJ, 2010) |
| "Neuropathic pain is a serious chronic disorder caused by lesion or dysfunction in the nervous systems." | ( Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K, 2010) |
| "Neuropathic pain is a common symptom associated with peripheral neuropathy and can be as or more disabling than the effects of nerve damage from the neuropathy." | ( Jefferies, K, 2010) |
| "Neuropathic pain is characterized by hypersensitivity to innocuous stimuli (tactile allodynia) that is nearly always resistant to NSAIDs or even opioids." | ( Hamamura, K; Inoue, K; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Tsuda, M; Uchida, T; Yoshida, M, 2010) |
| "Neuropathic pain is the most difficult pain to manage in the pain clinic, and sleep problems are common among patients with chronic pain including neuropathic pain." | ( Furuya, M; Hatakeyama, N; Horiuchi, H; Imai, S; Kinoshita, H; Kuzumaki, N; Matoba, M; Narita, M; Niikura, K; Senba, E; Suzuki, T; Takemura, Y; Tsukiyama, Y; Yamashita, A; Yamazaki, M; Yanase, M, 2011) |
| "Neuropathic pain is caused by damage or malfunctioning of the nervous system." | ( Käenmäki, M; Kalso, EA; Kambur, O; Kontinen, VK; Männistö, PT; Pusa, AM, 2011) |
| "Neuropathic pain is the most difficult type of pain to cure." | ( Deng, L; Gao, Y; Kong, F; Li, G; Liang, S; Liu, H; Liu, J; Liu, S; Wu, R; Xie, J; Xu, C; Zhu, G, 2011) |
| "Diabetic neuropathic pain is amongst the most difficult types of pain to treat mainly due to the lack of understanding of its etiology and inadequate relief with available drug therapy." | ( Chopra, K; Kuhad, A; Tiwari, V, 2011) |
| "Neuropathic pain is often "spontaneous" or "stimulus-independent." | ( Fields, HL; King, T; Lai, J; Okun, A; Porreca, F; Qu, C, 2011) |
| "Neuropathic pain is an intractable clinical problem, affecting millions of people worldwide." | ( Mei, XP; Ren, J; Xie, C; Xu, H; Xu, LX; Zhang, H; Zhou, Y, 2011) |
| "Neuropathic pain is a chronic pain condition that occurs and persists in a heterogeneous group of etiologically different diseases characterized by a primary lesion or dysfunction of the peripheral or central nervous system." | ( Arjun, M; Menon, N; Semwal, A; Sriram, D; Yogeeswari, P, 2011) |
| "Neuropathic pain is a chronic and intractable symptom associated with nerve injury." | ( Cho, YW; Hahm, ET; Kim, Y; Lee, JJ, 2011) |
| "Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments." | ( Carloni, F; Castellani, C; Drudi, F; Possenti, C; Santelmo, C; Tassinari, D, 2011) |
| "Neuropathic pain is a compilation of somatosensory, cognitive and emotional alterations developing following nerve injuries." | ( Machelska, H, 2011) |
| "Neuropathic pain is a clinical condition which remains poorly treated and combinations of pregabalin, an antagonist of the α2δ-subunit of Ca(2+) channels, with tapentadol, a μ-opioid receptor agonist/noradrenaline reuptake inhibitor, or with classical opioids such as oxycodone and morphine might offer increased therapeutic potential." | ( Christoph, T; De Vry, J; Schiene, K; Tallarida, RJ; Tzschentke, TM, 2011) |
| "Severe chronic neuropathic pain is a challenge to treat, and due to adverse effects of classical oral medication, optimal and effective dose levels are difficult to reach." | ( Hesselink, JM; Kopsky, DJ, 2012) |
| "Neuropathic pain is difficult to diagnose and difficult to treat with certainty." | ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic pain is therefore initiated by HCN2-driven action potential firing in Na(V)1." | ( Berrocoso, EM; Chen, L; Emery, EC; McNaughton, PA; Young, GT, 2011) |
| "The management of neuropathic pain is unsatisfactory, and new treatments are required." | ( Carr, FB; Géranton, SM; Hunt, SP; Liu, Q; Lumb, BM; Obara, I; Tochiki, KK, 2011) |
| "Peripheral neuropathic pain is a chronic condition that may produce plastic changes in several brain regions." | ( Alba-Delgado, C; Berrocoso, E; Borges, G; Horrillo, I; Meana, JJ; Mico, JA; Neto, F; Ortega, JE; Sánchez-Blázquez, P, 2012) |
| "Neuropathic pain is not accompanied by modifications in tonic LC activity after the onset of pain." | ( Alba-Delgado, C; Berrocoso, E; Borges, G; Horrillo, I; Meana, JJ; Mico, JA; Neto, F; Ortega, JE; Sánchez-Blázquez, P, 2012) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system and treatment of neuropathic pain remains a challenge." | ( Arani, MN; Banafshe, HR; Hamidi, GA; Mesdaghinia, A; Ramezani, MH; Talaei, SA, 2012) |
| "Diabetes-induced neuropathic pain is recognized as one of the most difficult type of pain to treat and conventional analgesics are well known to be partially effective or associated with potential toxicity." | ( Sharma, PL; Taliyan, R, 2012) |
| "Neuropathic pain is a chronic neurodegenerative disease." | ( Krishnan, UM; Muthuraman, A; Shanmugam, P; Singh, N; Thiagarajan, VR, 2013) |
| "Central neuropathic pain is a common debilitating symptom in patients with multiple sclerosis." | ( Hesselink, JM; Kopsky, DJ, 2012) |
| "When neuropathic pain is diagnosed, appropriate treatment is important in limiting the severe psychosocial impairment that can ensue with undertreated pain." | ( Pierce, DM; Shipstone, E, 2012) |
| "Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system resulting from trauma, infection, ischaemia, cancer or other causes such as chemotherapy." | ( Fornasari, D, 2012) |
| "Diabetes induced neuropathic pain is recognized as one of the most difficult types of pain to treat with conventional analgaesics." | ( Sharma, PL; Taliyan, R, 2012) |
| "Neuropathic pain is caused by neural damage or dysfunction and neuropathic pain-related symptoms are resistant to conventional analgesics." | ( Fukazawa, Y; Kiguchi, N; Kishioka, S; Kobayashi, Y; Saika, F, 2012) |
| "Neuropathic pain is a devastating neurological disease that seriously affects patients' quality of life." | ( Jiang, W; Liang, Y; Tao, L; Yu, J; Zhang, Z; Zhao, S, 2012) |
| "Neuropathic pain is common and difficult to treat." | ( Cheng, J; Fox, LE; Shen, J, 2012) |
| "Neuropathic pain is a common cause of pain after nerve injury, but its molecular basis is poorly understood." | ( Barres, B; Boroujerdi, A; Corpe, M; Deng, P; Eroglu, C; Kim, DS; Lee, J; Li, KW; Luo, ZD; Park, J; Peter Yu, Y; Sharp, K; Steward, O; Xu, ZC; Zaucke, F; Zhang, X; Zhou, CY, 2012) |
| "Chronic neuropathic pain is a debilitating disease caused by a lesion of the somatosensory nervous system." | ( Dahan, A; Niesters, M, 2012) |
| "Neuropathic pain is a refractory clinical problem." | ( Chen, L; Li, YQ; Mei, XP; Wang, LY; Wang, W; Wu, D; Xu, LX; Zhang, H; Zhang, T, 2013) |
| "Peripheral neuropathic pain is a serious side effect of paclitaxel treatment." | ( Abe, K; Chiba, T; Hama, T; Katagiri, N; Kawakami, K; Saduka, M; Taguchi, K; Utsunomiya, I, 2012) |
| "Neuropathic pain is a chronic pain condition resulting from neuronal damage, and is usually treated with pregabalin or gabapentin, which are structurally related to γ-aminobutyric acid (GABA) and are originally developed as anticonvulsant drugs." | ( Fukasawa, H; Inoue, K; Ito, A; Muratake, H; Shudo, K; Sugiyama, K; Suzuki, H; Toda, T; Tsuda, M, 2012) |
| "Although trigeminal neuropathic pain is one of the most common chronic pain syndromes, the etiology is still unknown." | ( Fukuda, A; Furukawa, T; Inoue, K; Kumada, T; Sato, K; Watanabe, M; Wei, B, 2013) |
| "Neuropathic pain is a debilitating condition, and pharmacotherapy is the most established treatment strategy." | ( Miyauchi, S; Sumitani, M; Yamada, Y, 2012) |
| "Neuropathic pain is a well-known type of chronic pain caused by damage to the nervous system." | ( Cho, HT; Choi, JI; Im, YB; Jee, MK; Kang, SK; Kwon, OH, 2012) |
| "Neuropathic pain is a challenge in children with burn sequelae." | ( Hidalgo, G; Orellana Silva, M; Saavedra, R; Valenzuela, F; Yañez, V, 2013) |
| "Neuropathic pain is a debilitating condition that is often resistant to common analgesics, such as opioids, but is sensitive to some antidepressants, an effect that seems to be mediated by spinal cord 5-HT3 receptors." | ( Bonacorso, HG; Fachinetto, R; Ferreira, J; Machado, P; Martins, MA; Oliveira, SM; Pinheiro, Fde V; Pinheiro, Kde V; Villarinho, JG; Zanatta, N, 2013) |
| "Neuropathic pain is an area of unmet clinical need." | ( Edwards, SR; Smith, MT; Wyse, BD, 2013) |
| "Neuropathic pain is a chronic debilitating disease that is often unresponsive to currently available treatments." | ( Bangsow, T; Geisslinger, G; Heidler, J; Kallenborn-Gerhardt, W; Lu, R; Schmidtko, A; Syhr, KM; von Melchner, H, 2013) |
| "Neuropathic pain is difficult to treat." | ( Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2013) |
| "Multifactor neuropathic pain is one of the most frequent symptoms in AIDS patients and analgesic treatment is primarily based on the use of drug combination of opioids, tricyclic antidepressants and antiepileptics." | ( Cannata, F; Canneti, A; Di Marco, P; Luzi, M; Pasqualitto, F; Reale, C; Spinoglio, A, 2013) |
| "Neuropathic pain is commonly associated with cancer." | ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Treating neuropathic pain is a major clinical challenge, and the underlying mechanisms of neuropathic pain remain elusive." | ( Huang, ZJ; Liu, S; Liu, YP; Song, AA; Song, XJ; Zhang, YK, 2013) |
| "Neuropathic pain is frequently characterized by spontaneous pain (ie, pain at rest) and, in some cases, by cold- and touch-induced allodynia." | ( De Felice, M; Guo, W; King, T; Ossipov, MH; Porreca, F; Wang, R, 2013) |
| "Neuropathic pain is difficult to control and patient response to current treatment is often inadequate." | ( Aoki, Y; Arai, G; Eguchi, Y; Inoue, G; Ishikawa, T; Kamoda, H; Miyagi, M; Ohtori, S; Oikawa, Y; Orita, S; Ozawa, T; Sakuma, Y; Suzuki, M; Takahashi, K; Toyone, T; Yamaguchi, A; Yamashita, M, 2013) |
| "Prevalence of neuropathic pain is high after major surgery." | ( Berta, T; Ji, RR; Liu, XJ; Lü, N; Park, CK; Serhan, CN; Xu, ZZ, 2013) |
| "Neuropathic pain is a common chronic pain condition that can be challenging to treat, particularly for non-specialists." | ( Baranowski, AP; Lee, J; Price, C; Smith, BH, 2013) |
| "Cancer-related neuropathic pain is common; it can be disease related or related to the acute or chronic effects of cancer treatment." | ( Fallon, MT, 2013) |
| "One feature of neuropathic pain is a reduced spinal gamma-aminobutyric acid (GABA)-ergic inhibitory function." | ( Chung, JM; Chung, K; Kim, HY; Lu, Y; Wang, J; Yowtak, J, 2013) |
| "Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat." | ( Chen, L; Mao, J, 2013) |
| "Neuropathic pain is a debilitating condition resulting from damage to sensory transmission pathways in the peripheral and central nervous system." | ( Anderson, EM; Bokrand-Donatelli, Y; Caudle, RM; Mustafa, G; Neubert, JK, 2013) |
| "Neuropathic pain is pain arising as a direct consequence of a lesion or disease affecting the somatosensory system." | ( Barrot, M; Bohren, Y; Daniel, D; Fournel, S; Freund-Mercier, MJ; Hein, L; Hugel, S; Kremer, M; Megat, S; Petitjean, H; Schlichter, R; Tessier, LH; Yalcin, I, 2013) |
| "Neuropathic pain is an intractable clinical problem." | ( Liu, R; Mei, XP; Wang, H; Wang, W; Wu, D; Xie, C; Xu, LX; Zhang, H; Zhang, J, 2013) |
| "Neuropathic pain is a condition that is still not well understood, although it affects a significantly high percentage of the population." | ( Márquez-Rivas, J; Mayorga-Buiza, MJ; Monge-Márquez, ME; Rivero-Garvía, M, 2013) |
| "Neuropathic pain is one of the major problems of patients with spinal cord injury (SCI), which remains refractory to treatment despite a variety of therapeutic approach." | ( Kim, SE; Kim, YK; Lee, Y; Shin, HI; Yoon, EJ, 2013) |
| "Neuropathic pain is defined as pain primarily initiated by dysfunction of the peripheral or central nervous system." | ( Brandow, AM; Farley, RA; Panepinto, JA, 2014) |
| "Such neuropathic pain is refractory to common analgesics and represents a challenging clinical issue." | ( Cao, SE; Li, P; Liu, G; Tian, J; Wang, Y; Zhang, X, 2013) |
| "Neuropathic pain is one of the most common complications of diabetes mellitus." | ( Banafshe, HR; Hamidi, GA; Mirhashemi, SM; Mokhtari, R; Noureddini, M; Shoferpour, M, 2014) |
| "Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a challenging clinical issue." | ( Guo, Z; Hao, J; Jin, H; Man, Y; Mi, W; Su, X; Sun, X; Wang, X, 2014) |
| "Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions." | ( Aarts, L; Brines, M; Cerami, A; Dahan, A; Dunne, A; Niesters, M; Swartjes, M; van Velzen, M, 2014) |
| "Neuropathic pain is a serious physical disabling condition resulting from lesion or dysfunction of the peripheral sensory nervous system." | ( Felix, R; Granados-Soto, V; Pineda-Farias, JB; Sandoval, A; Zoidis, G, 2014) |
| "The management of neuropathic pain is still a major challenge because of its unresponsiveness to most common treatments." | ( Chang, R; Guo, Q; Huang, C; Li, Q; Song, Z; Yang, D; Zhu, X, 2014) |
| "Neuropathic pain is characterized by spontaneous pain, hyperalgesia, and allodynia." | ( Chen, IJ; Chen, JY; Cheng, KI; Chu, LW; Dai, ZK; Lin, TC; Liou, JC; Wu, BN, 2014) |
| "Peripheral neuropathic pain is a common complication in the diabetic patients, and the underlying central mechanism remains unclear." | ( Li, H; Li, W; Wang, P, 2014) |
| "Neuropathic pain is a chronic condition resulting from neuronal damage." | ( Amano, Y; Fukasawa, H; Ito, A; Muratake, H; Nagae, M; Shudo, K; Sugiyama, K; Suzuki, H, 2014) |
| "Neuropathic pain is a severe painful pathology that is difficult to treat." | ( Andrade, EL; Calixto, JB; do Nascimento Cordeiro, M; Ferreira, J; Gomez, MV; Rigo, FK; Rosa, F; Tonello, R; Trevisan, G, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| "Neuropathic pain is a major health issue that represents considerable social and economic burden worldwidely." | ( Lu, J; Wang, Y; Xie, J; Yue, Z; Zhang, R, 2014) |
| "Chronic neuropathic pain is a common consequence of spinal cord injury (SCI), develops over time and negatively impacts quality of life, often leading to substance abuse and suicide." | ( Hassler, SN; Hulsebosch, CE; Johnson, KM, 2014) |
| "Chronic neuropathic pain is often refractory to standard pharmacological treatments." | ( Almog, S; Eisenberg, E; Ogintz, M, 2014) |
| "Neuropathic pain is clinically challenging because it is resistant to alleviation by morphine." | ( Makuch, W; Mika, J; Pilat, D; Popiolek-Barczyk, K; Rojewska, E, 2014) |
| "Neuropathic pain is a challenge for physicians and basic science researchers, because it often does not respond to routine treatment." | ( Du, D; Jiang, W; Wang, J; Yu, T; Zhang, X, 2015) |
| "Neuropathic pain is a common complication of treatment with the anti-neoplastic drug paclitaxel." | ( Fink, DJ; Mata, M; Wang, S; Wu, I; Wu, Z, 2015) |
| "The treatment of neuropathic pain is a medical challenge." | ( Chiarlone, R; Fogliardi, A; Intelligente, F; Irace, C; Lanzilotta, M; Lattanzi, S; Palomba, R; Provinciali, L; Storelli, E; Zampi, M, 2014) |
| "Neuropathic pain is commonly treated with GABA analogues, steroids or non-steroidal anti-inflammatory drugs (NSAIDs)." | ( Banks, ML; Bradshaw, HB; Crowe, MS; Gujjar, R; Kinsey, SG; Leishman, E; Mahadevan, A, 2015) |
| "Neuropathic pain is believed to be influenced in part by inflammatory processes." | ( Al Nimer, F; Carlström, KE; Dominguez, CA; Lindblom, RP; Ortlieb Guerreiro-Cacais, A; Piehl, F; Zhang, XM, 2014) |
| "Treatments for neuropathic pain are either not fully effective or have problematic side effects." | ( Dickenson, AH; Friend, LV; Gonçalves, L, 2015) |
| "Neuropathic pain is a large unmet medical need." | ( Rice, AS; Smith, MT, 2015) |
| "Neuropathic pain is a severe clinical problem, often appearing as a co-symptom of many diseases or manifesting as a result of damage to the nervous system." | ( Jurga, AM; Kwiatkowski, K; Makuch, W; Malek, N; Mika, J; Przewlocka, B; Rojewska, E; Starnowska, J; Wasylewski, M, 2015) |
| "Neuropathic pain is caused by long-term modifications of neuronal function in the peripheral nervous system, the spinal cord, and supraspinal areas." | ( Nevian, T; Santello, M, 2015) |
| "Neuropathic pain is common in peripheral nerve injury and often fails to respond to ordinary medication." | ( Alberch, J; Boadas-Vaello, P; Puig, T; Turrado, C; Verdú, E; Vidal-Sancho, L; Xifró, X, 2015) |
| "Migraine and neuropathic pain are common causes of chronic pain." | ( Balog, A; Majláth, Z; Tajti, J; Vécsei, L, 2015) |
| "Neuropathic pain is a common and severely disabling state that affects millions of people worldwide." | ( Gao, Y; Huang, LP; Liang, SD; Liu, SM; Peng, LC; Qiu, SY; Song, MM; Wu, B; Wu, Q; Xiong, W; Xu, LY; Yi, Y; Zhang, CP, 2015) |
| "Neuropathic pain is a condition resulting from injury to the peripheral and/or central nervous system." | ( Ahmed, SU; Chen, L; Cohen, A; Houghton, M; Mao, J; St Hillary, K; Vo, T; Zhang, Y, 2015) |
| "Neuropathic pain is difficult to relieve with standard analgesics and tends to be resistant to opioid therapy." | ( Davis, MP, 2015) |
| "Neuropathic pain is a prevalent and distressing problem faced by people with life-limiting illness that is often difficult to palliate." | ( Clark, K; Currow, DC; Doogue, M; Lovell, M; Quinn, SJ; Sanderson, C, 2015) |
| "Neuropathic pain is a chronic condition that is difficult to be treated." | ( Bharatham, BH; Farouk, AA; Gopalsamy, B; Perimal, EK; Sulaiman, MR; Zulazmi, NA, 2015) |
| "Neuropathic pain is often severe." | ( Chang, JW; Jung, HH; Kim, J; Kim, KH; Kim, SJ; Lee, SE; Ryu, SB; Shin, J, 2016) |
| "Neuropathic pain is often insensitive to morphine." | ( Araki, K; Matsushita, Y; Mukae, T; Uchida, H; Ueda, H, 2015) |
| "Neuropathic pain is associated with severe chronic sensory disturbances characterized by spontaneous pain, increased responsiveness to painful stimuli (hyperalgesia) and pain perceived in response to non-noxious stimuli (allodynia)." | ( Bedi, O; Deshmukh, R; Kaur, G; Kumar, P; Sharma, N; Singh, S, 2016) |
| "Neuropathic pain is a very troublesome and difficult pain to treat." | ( Huang, EY; Law, PY; Loh, HH; Tao, PL; Yang, PP; Yeh, GC, 2015) |
| "Neuropathic pain is a debilitating condition for which the development of effective treatments has been limited by an incomplete understanding of its molecular basis." | ( Cordeiro Matos, S; Séguéla, P; Zhang, Z, 2015) |
| "Neuropathic pain is considered as a special type of different pain conditions." | ( Kiss, G, 2015) |
| "Although neuropathic pain is a common consequence after CNS injuries, little attention has been given to neuropathic pain symptoms after TBI." | ( Adcock, JP; Govind, V; Levin, BE; Maudsley, AA; Widerström-Noga, E, 2016) |
| "Neuropathic pain is frequently comorbid with sleep disturbances." | ( Chen, JF; Cheng, NN; Hu, ZZ; Huang, ZL; Liu, YY; Qu, WM; Wang, TX; Yin, D, 2016) |
| "Neuropathic pain is a series of well-known conditions caused by diseases or lesions to the somatosensory system." | ( Escudeiro, G; Nascimento, OJ; Pessoa, BL, 2015) |
| "Neuropathic pain is often associated with behavioral depression." | ( Leitl, MD; Negus, SS, 2016) |
| "Neuropathic pain is difficult to treat, and the available options are often inadequate." | ( Kern, KU; Weiser, T, 2015) |
| "Neuropathic pain is difficult to treat and available options are frequently not sufficient." | ( Kern, KU; Weiser, T, 2015) |
| "Neuropathic pain is caused by a lesion or disease affecting the somatosensory system and is difficult to manage, often proving refractory to existing treatments." | ( Allegri, M; Baron, R; Correa-Illanes, G; Hans, G; Mayoral Rojals, V; Mick, G; Serpell, M, 2016) |
| "Neuropathic pain is one of the most debilitating pain conditions, yet no therapeutic strategy has been really effective for its treatment." | ( Aissouni, Y; Balayssac, D; Bayet-Robert, M; Chalus, M; Dalmann, R; Daulhac, L; El Guerrab, A; Eschalier, A; Ferrier, J; Graveron-Demilly, D; Marchand, F; Pinguet, J; Richard, D, 2015) |
| "Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a clinical challenge." | ( Fang, Y; Ge, WH; Zhang, L; Zhou, HH; Zhou, QG, 2016) |
| "Diabetic neuropathic pain is reduced with tight glycemic control." | ( Candiotti, KA; Mei, S; Rodriguez, Y; Yang, J; Zhang, YP, 2016) |
| "Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment." | ( Batterham, A; Brookes, ME; Eldabe, S, 2017) |
| "Neuropathic pain is the result of injury to the nervous system, and different animal models have been established to meet the manifestations of neuropathy." | ( Aranda, N; Castillo, R; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Zanetta, P, 2016) |
| "Neuropathic pain is one of the key features of (classical) Fabry disease (FD)." | ( Biegstraaten, M; Hollak, CE; Linthorst, GE; Schuller, Y; Van Schaik, IN, 2016) |
| "Neuropathic pain is a frequent complication of spinal cord injury (SCI), still refractory to conventional treatment." | ( Adler, NS; Coronel, MF; De Nicola, AF; González, SL; Labombarda, F; Raggio, MC, 2016) |
| "Neuropathic pain is becoming an intractable health threat, with its profound effect on quality of life, thus posing a major challenge to clinical therapy." | ( Chen, H; Ge, AQ; Jiang, K; Miao, B; Sun, L; Yan, M; Zhuang, Y, 2016) |
| "Neuropathic pain is still one of the most difficult pain states to be treated due to the lack of effective drugs." | ( Bujalska-Zadrożny, M; Dawidowski, M; de Cordé, A; Kleczkowska, P; Kogut, E, 2016) |
| "Neuropathic pain is absent from the early stages of periodontal disease possibly due to neurite retraction." | ( Cueno, ME; Kamimoto, A; Kamio, N; Kurita-Ochiai, T; Ochiai, K; Saito, Y; Seki, K, 2016) |
| "Neuropathic pain is treated using serotonin norepinephrine reuptake inhibitors with mixed results." | ( Banerjee, T; Holden, JE; Jeong, Y; Wagner, M, 2016) |
| "Neuropathic pain is initiated or caused due to the primary lesion or dysfunction in the nervous system and is proposed to be linked to a cascade of events including excitotoxicity, oxidative stress, neuroinflammation and apoptosis." | ( Areti, A; Komirishetty, P; Kumar, A; Sistla, R, 2016) |
| "Neuropathic pain is associated with impaired inhibitory control of spinal dorsal horn neurons, which are involved in processing pain signals." | ( Benke, D; Malherbe, P; Ralvenius, WT; Zemoura, K, 2016) |
| "Neuropathic pain is a frequent complication of spinal cord injury (SCI), still refractory to conventional treatment." | ( Adler, NS; Coronel, MF; De Nicola, AF; González, SL; Labombarda, F; Raggio, MC; Sánchez Granel, ML, 2016) |
| "Chronic neuropathic pain is a debilitating condition that remains difficult to treat." | ( Chen, H; Chen, SR; Hittelman, WN; Li, L; Pan, HL; Wen, L; Xie, JD, 2016) |
| "Peripheral neuropathic pain is a consequence of an injury/disease of the peripheral nerves." | ( Alves-Filho, JC; Bassi, GS; Bozzo, TA; Cunha, FQ; Cunha, TM; Ferreira, SH; Kusuda, R; Sant'Anna, MB; Souza, GR, 2016) |
| "Neuropathic pain is a common neurobiological disease involving multifaceted maladaptations ranging from gene modulation to synaptic dysfunction, but the interactions between synaptic dysfunction and the genes that are involved in persistent pain remain elusive." | ( Huang, ZZ; Li, D; Liu, CC; Ma, C; Ou-Yang, HD; Wei, JY; Wu, SL; Xin, WJ; Xu, T; Zhang, XL, 2016) |
| "Neuropathic pain is a common neurobiological disease involving multifaceted maladaptations ranging from gene modulation to synaptic dysfunction, but the underlying molecular mechanisms remain elusive." | ( Huang, ZZ; Li, D; Liu, CC; Ma, C; Ou-Yang, HD; Wei, JY; Wu, SL; Xin, WJ; Xu, T; Zhang, XL, 2016) |
| "Chronic neuropathic pain is a common symptom of multiple sclerosis (MS)." | ( Baker, G; Caliaperumal, J; Colbourne, F; Kerr, BJ; Paylor, JW; Potter, LE; Suh, JS; Tenorio, G; Winship, I, 2016) |
| "Neuropathic pain is considered as one of the most difficult types of pain to manage with conventional analgesics." | ( Hu, XY; Li, M; Li, W; Luo, ZJ; Wang, Z; Xu, F; Yang, L; Ye, ZX; Zhu, C, 2016) |
| "Neuropathic pain is a severe and unbearable condition which arises due to activation of peripheral nociceptors after tissue damage, neuropathic pain is caused from anomalous physiology of central or peripheral nervous system and it may not be related to the ongoing tissue damage or inflammation." | ( Goel, R; Tyagi, N, 2016) |
| "Trigeminal neuropathic pain is described as constant excruciating facial pain." | ( Donahue, R; Jamal, AB; Kaushal, R; Ma, F; Taylor, BK; Westlund, KN; Zhang, L, 2016) |
| "Neuropathic pain, is caused by damage or disease affecting the somatosensory nervous system, leads to deterioration of the quality of life of patients." | ( Dobrogowski, J; Kocot-Kępska, M; Mika, J; Przeklasa-Muszyńska, A; Wiatr, M, 2016) |
| "Neuropathic pain is under-treated, with a detrimental effect on quality of life, partly because of low treatment efficacy, but also because pathophysiological mechanisms are not fully elucidated." | ( Durante, M; Galeotti, N; Ghelardini, C; Lucarini, L; Masini, E; Sanna, MD, 2017) |
| "Neuropathic pain is a debilitating clinical condition with few efficacious treatments, warranting development of novel therapeutics." | ( Chen, L; Cheng, Z; Han, Y; Hu, L; Liu, WT; Lu, L; Pan, C; Wang, C; Yang, Y, 2017) |
| "Neuropathic pain is a common side-effect of chemotherapy." | ( Colvin, L; Galley, HF; Lowes, DA; McCormick, B; Torsney, C, 2016) |
| "Neuropathic pain is a common and distressing symptom in thoracic surgical patients." | ( Ambrosio, F; Freo, U; Ori, C, 2017) |
| "Neuropathic pain is one of the prevalent complications of diabetes mellitus (DM)." | ( Baluchnejadmojarad, T; Kiasalari, Z; Mahmoudi, N; Rahmani, T; Roghani, M, 2017) |
| "Neuropathic pain is still considered as incurable disease as current therapies are not ideal in terms of efficacy and tolerability." | ( Wang, C, 2017) |
| "Neuropathic pain is more severe, with significant disability." | ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "Neuropathic pain is a type of chronic pain caused by nervous system damage and dysfunction." | ( Gong, Y; Jia, T; Jiang, C; Li, G; Li, L; Liang, S; Liu, H; Liu, S; Rao, S; Shi, L; Wu, B; Yi, Z; Ying, M; Yuan, H; Zhang, C; Zhang, T; Zhao, S; Zou, L, 2017) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population." | ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Neuropathic pain is a type of chronic pain that results from dysfunctions of the somatosensory nerve system." | ( Fan, D; Ma, L; Xi, K; Xie, X; Zhang, W, 2017) |
| "Neuropathic pain is often treated with gabapentinoids (pregabalin, gabapentin), but gabapentinoid-induced somnolence sometimes prevents patients from using these agents." | ( Abe, H; Hozumi, J; Ikegami, K; Inoue, R; Kawahara, K; Kogure, T; Sumitani, M; Yamada, Y, 2017) |
| "Neuropathic pain is a debilitating pathological condition that is poorly understood." | ( Faingold, CL; Premkumar, LS; Samineni, VK, 2017) |
| "Neuropathic pain is difficult to manage and treat." | ( Inoue, S; Johanek, LM; Sluka, KA, 2017) |
| "Neuropathic pain is a chronic disease with hallmarks such as chronic allodynia and hyperalgesia." | ( Jiang, L; Li, S; Liu, Y; Long, Z; Tan, B; Wang, L; Wu, Y; Zheng, L, 2017) |
| "Neuropathic pain is a common symptom in many diseases of the nervous system." | ( Aldington, D; Carr, DB; Chen, J; Cole, P; Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "The prevalence of neuropathic pain is high in the general population, and high priority is given to the management of this pain condition." | ( Lloret-Linares, C; Perrot, S; Trouvin, AP, 2017) |
| "Neuropathic pain is a common symptom in many diseases of the peripheral nervous system." | ( Aldington, D; Bell, RF; Derry, S; Duehmke, RM; Moore, RA; Wiffen, PJ, 2017) |
| "Neuropathic pain is a common diabetic complication." | ( Courteix, C; Davin, N; Eschalier, A; Farges, MC; Privat, AM; Rondón, LJ; Sion, B; Vasson, MP, 2018) |
| "SNL induced- neuropathic pain is transmitted to the primary somatosensory area and parietal region through the cingulum bundle and limbic system." | ( Jeong, KY; Kang, JH, 2018) |
| "Neuropathic pain is caused by lesion or disease of the nervous system, which results in abnormal spontaneous and evoked pain." | ( Han, F; Ji, C; Li, X; Sun, D; Wang, H; Xu, Y; Yao, X; Zhang, H, 2017) |
| "Neuropathic pain is an integral component of several chronic pain conditions and poses a major health problem worldwide." | ( Bali, KK; Kuner, R, 2017) |
| "Neuropathic pain is a chronic pain condition, which is resistant to therapy." | ( Nasirinezhad, F; Saffarpour, S, 2017) |
| "The treatment of neuropathic pain is very complex and there are few drugs approved for this purpose." | ( da Silva, ABF; de Sousa, AG; Honorio, KM; Lipinski, CF; Oliveira, AA; Oliveira, PR; Pereira, EB; Romero, RAF; Weber, KC, 2017) |
| "Neuropathic pain is one of the most important challenges in public health." | ( Almanza, A; Canseco-Alba, A; Coffeen, U; León-Olea, M; Mercado, F; Pellicer, F; Simón-Arceo, K, 2018) |
| "Neuropathic pain is a severe condition with unsatisfactory treatments." | ( Bonazza, V; Borsani, E; Buffoli, B; Reiter, RJ; Rezzani, R; Rodella, LF, 2017) |
| "Patients with neuropathic pain are highly motivated for pain relief, and as motivational factors such as expectations of reward, as well as pain processing in itself, are related to the dopaminergic system, it can be speculated that dopamine release contributes to placebo effects in neuropathic pain." | ( Baastrup, C; Benedetti, F; Grosen, K; Hall, KT; Jensen, TS; Kaptchuk, TJ; Moslemi, K; Petersen, GL; Price, DD; Skyt, I; Svensson, P; Vase, L, 2018) |
| "Neuropathic pain is difficult to treat, and the efficacy of recommended drugs remains limited." | ( Delage, N; Marcaillou, F; Morel, V; Pereira, B; Picard, P; Pickering, G, 2017) |
| "Neuropathic pain is induced by unilateral sciatic chronic constriction injury (CCI), and while enduring relief of light touch sensitivity (mechanical allodynia) in both wild type (WT) and IL-10 KO mice was observed following DM/pDNA-IL-10 co-therapy, transient reversal from allodynia was observed following i." | ( Jantzie, LL; Mellios, N; Milligan, ED; Noor, S; Sanchez, JE; Sun, MS; Vanderwall, AG; Yang, XO, 2018) |
| "Neuropathic pain is one of the symptoms of CIPN." | ( Kaushik, P; Parvez, S; Tabassum, H; Waseem, M, 2018) |
| "Neuropathic pain is relatively common and occurs in approximately 6-8% of the population." | ( Caumo, W; Dos Santos, ARS; Martins, DF; Martins, TC; Medeiros, LF; Nucci-Martins, C; Siteneski, A; Souza, A; Torres, ILS, 2018) |
| "Neuropathic pain is an intractable and complex disease." | ( Gui, Y; Guo, Q; Li, A; Li, G; Ruan, X; Zhang, J; Zou, W, 2018) |
| "Neuropathic pain is a complex, chronic pain condition and the treatment is a major clinical challenge." | ( Chen, J; Li, H; Li, N; Lim, G; Ma, W; McCabe, MF; Yang, Y; Zhao, W, 2018) |
| "Neuropathic pain is among the most common and difficult-to-treat types of chronic pain and is associated with sodium channel malfunction." | ( Liang, X; Su, R; Yu, G, 2018) |
| "Neuropathic pain is a subset of chronic pain that is caused by neurons that are damaged or firing aberrantly in the peripheral or central nervous systems." | ( Abdulrazeq, HF; Ali, M; Hamad, MK; He, K; Herzallah, MM; Kamal, N; Luceri, R; Mammis, A; Mustafa, AM; Nakhla, J, 2018) |
| "Neuropathic pain is a worldwide health problem with no consensus regarding its optimal therapy." | ( Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR, 2018) |
| "Neuropathic pain is a common clinical complication of nerve injury, and the effective treatment of neuropathic pain is still challenging." | ( Guo, S; Li, A; Wang, S, 2016) |
| "Cancer-related neuropathic pain is sometimes unresponsive to multidrug treatment." | ( Akechi, T; Kataoka, T; Kimura, K; Kondo, Y; Naiki, T; Sakamoto, N; Sato, N; Sugiyama, Y; Tasaki, Y, 2018) |
| "Neuropathic pain is one of the severe complications that results from diabetic neuropathy." | ( Bai, HH; Hu, XD; Liu, JP; Suo, ZW; Yang, L; Yang, X; Zhao, JY, 2018) |
| "Ongoing neuropathic pain is difficult to treat." | ( Anderson, M; Chen, X; Chen, Z; Dong, X; Grenald, SA; Guan, Y; He, SQ; Raja, SN; Shu, B; Stephens, KE; Tiwari, V; Yang, F; Zhang, T; Zheng, Q, 2018) |
| "Neuropathic pain is a severe health problem for which there is a lack of effective therapy." | ( Yu, M; Zhang, X; Zhao, Y, 2018) |
| "Neuropathic pain is developed at late phase after SCI and a single dose of 17β-estradiol (100, 300 μg/kg) were administered to rats with neuropathic pain after SCI through intravenous injection." | ( Choi, HY; Ju, BG; Lee, JY; Yune, TY, 2018) |
| "Neuropathic pain is associated with abnormal sensitivity of the central nervous system." | ( Chang, JW; Jung, HH; Koh, CS; Kong, C; Lee, J; Shin, J; Yoon, MS, 2018) |
| "Neuropathic pain is often associated with depression." | ( Gong, DY; Hai, KR; Jiang, HX; Ke, BW; Liu, J; Ma, G; Yang, Z; Zhou, C, 2019) |
| "Neuropathic pain is a chronic and intractable pain, with very few effective analgesics." | ( Chen, H; Huo, X; Li, B; Liu, J; Ma, W; Shi, K; Wang, H; Wang, X; Xie, K; Yu, Y, 2018) |
| "Chronic neuropathic pain is an important healthcare issue with significant emotional components." | ( Ji, G; Neugebauer, V; Thompson, JM; Yakhnitsa, V, 2018) |
| "Neuropathic pain is also a disturbing component of SCI." | ( Afshari, K; Dehdashtian, A; Dehpour, AR; Ebrahimi, MA; Faghir-Ghanesefat, H; Haddadi, NS; Haj-Mirzaian, A; Iranmehr, A; Javidan, AN; Mohammadi, F; Rahimi, N; Tavangar, SM, 2018) |
| "Paclitaxel-induced neuropathic pain is a major dose-limiting side effect of paclitaxel therapy." | ( Duggett, NA; Flatters, SJL; Griffiths, LA; Pitcher, AL, 2018) |
| "Neuropathic pain is a common health problem that affects millions of people worldwide." | ( Kadhim, S; Lambert, DG; McDonald, J, 2018) |
| "Neuropathic pain is associated with several conditions such as surgery, cancer, and diabetes and can be induced experimentally." | ( Aranda, N; Miranda, HF; Noriega, V; Poblete, P; Prieto, JC; Sierralta, F, 2018) |
| "Neuropathic pain is a severe and chronic neurological disease caused by injury or disease of the somatosensory system." | ( Chen, G; Chen, M; Liu, D; Liu, H; Ma, L; Meng, C; Wang, L; Zhang, X, 2018) |
| "Neuropathic pain is a debilitating chronic syndrome that is often refractory to currently available analgesics." | ( Carcelén, M; de la Fuente, R; Francés, R; García, R; Hurlé, MA; Llorca, J; Tramullas, M; Velategui, S, 2018) |
| "Neuropathic pain is a chronic condition that is challenging to treat." | ( Alba-Delgado, C; Berrocoso, E; Llorca-Torralba, M; Mico, JA, 2018) |
| "Neuropathic pain is a major public health problem." | ( Ba, X; Deng, Q; Hao, Y; Jiang, C; Sun, W; Xiao, L; Xiong, D; Yang, S; Yu, Z; Zhou, Q, 2020) |
| "Neuropathic pain is one of the most important types of chronic pain." | ( Alves-Filho, JC; Cecilio, NT; Cunha, FQ; Cunha, TM; Davoli-Ferreira, M; Ferreira, DW; Fonseca, MM; Guimaraes, RM; Kusuda, R; Lopes, AH; Nachbur, U; Santa-Cecília, FV; Souza, GR; Teixeira, MM; Zamboni, DS, 2019) |
| "Neuropathic pain is a serious public health problem and has a strong affective-motivational component that makes it difficult to treat." | ( Antunes, GF; Assis, DV; Gouveia, F; Kuroki, M; Martinez, RCR; Oliveira, CC; Pagano, RL; Santos, LCT; Seno, MDJ, 2018) |
| "The mechanism of neuropathic pain is complex and unclear." | ( Jurga, A; Makuch, W; Mika, J; Piotrowska, A; Rojewska, E, 2018) |
| "The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain." | ( Gadhe, CG; Jeong, KS; Kim, GH; Lee, JY; Lim, EJ; Lim, KS; Lim, SM; Pae, AN; Son, WS; Yang, HK, 2018) |
| "Neuropathic pain is a major worldwide health problem." | ( Chao, TH; Chen, JH; Yen, CT, 2018) |
| "Neuropathic pain is a complication of cancer and diabetes mellitus and the most commonly used drugs in the treatment of the diabetic neuropathic pain have only limited efficacy." | ( Miranda, HF; Noriega, V; Poblete, P; Prieto, JC; Sierralta, F; Zepeda, RJ, 2019) |
| "Neuropathic pain is associated with persistent changes in gene expression in primary sensory neurons, but the underlying epigenetic mechanisms that cause these changes remain unclear." | ( Chen, H; Chen, SR; Pan, HL; Zhang, J, 2018) |
| "Neuropathic pain is an intractable disease with few definitive therapeutic options." | ( Li, YX; Liu, N; Ma, H; Ma, L; Sun, T; Tan, H; Wang, B; Yang, M; Yu, J; Zhang, G, 2018) |
| "Neuropathic pain is a well-known type of chronic pain caused by damage to the nervous system." | ( Poonit, K; Sun, C; Weng, W; Yan, H; Yao, C; Zhang, F; Zhou, X, 2019) |
| "Neuropathic pain is an unavoidable treatment-related adverse event among patients with head and neck cancer who are undergoing radiotherapy." | ( Argyriou, AA; Chen, MY; Chen, P; Chow, E; Gaertner, J; Huang, X; Hui, X; Jiang, J; Li, H; Li, J; Li, Y; Mai, HQ; Rong, X; Shen, Q; Simone, CB; Tang, Y; Xu, Y; Zheng, D; Zhou, L, 2019) |
| "Neuropathic pain is considered to be pathological in nature and has been shown to involve, at least partially, dysregulated inflammatory processes." | ( Nomikos, M; Saadé, N; Safieh-Garabedian, B, 2019) |
| "Neuropathic pain is a chronic pain condition caused by damage or dysfunction of the central or peripheral nervous system." | ( Chen, S; Dai, Q; Han, K; Huang, L; Li, D; Liang, D; Wang, J; Zhang, M, 2018) |
| "Neuropathic pain is generally resistant to currently available treatments, and it is often a consequence of nerve injury due to surgery, diabetes or infection." | ( Gong, Y; Liang, S; Liu, S; Zou, L, 2019) |
| "Neuropathic pain is a significant public health challenge, yet the underlying mechanisms remain poorly understood." | ( Barbosa, C; Cummins, TR; Pei, Z; Strong, JA; Xiao, Y; Xie, W; Zhang, JM, 2019) |
| "Neuropathic pain is a devastating chronic condition and effective treatments are still lacking." | ( Choi, H; Han, IB; Jo, MJ; Joshi, HP; Kim, J; Kim, JK; Kim, KT; Kim, S; Kim, SB; Kumar, H; Kyung, JW; Sohn, S, 2019) |
| "Neuropathic pain is a complex disorder associated with emotional and cognitive deficits that may impair nociceptive manifestations." | ( Baños, JE; Bilecki, W; Dickenson, AH; Gonçalves, L; Lara-Mayorga, IM; Maldonado, R; Martínez-Navarro, M; Negrete, R; Przewłocki, R; Wawrzczak-Bargieła, A, 2019) |
| "PERSPECTIVE: Neuropathic pain is difficult to treat and the exact mechanisms remain unknown." | ( Delphi, L; Rezayof, A; Tolou-Dabbaghian, B, 2019) |
| "Neuropathic pain is a debilitating form of treatment-resistant chronic pain caused by damage to the nervous system." | ( Ali, A; Banday, J; Bano, N; Bhat, AQ; Dar, MJ; Dar, MS; Nalli, Y; Rafia, B; Rasool, JU; Sarkar, AR; Vishwakarma, RA, 2019) |
| "Neuropathic pain is caused by sensory nerve injury, but effective treatments are currently lacking." | ( Aoki, J; Hibi, H; Kano, K; Kiyama, H; Kobayashi, H; Kobayashi, M; Konishi, H; Sayo, A, 2019) |
| "Pediatric neuropathic pain is caused by a spectrum of disorders that are generally challenging to treat." | ( Adams, TL; Anderson, A; Tham, SW; Windsor, RB, 2019) |
| "Neuropathic pain is a major public health problem because it has a considerable impact on life quality of patients." | ( Gao, W; Guo, J; Li, H; Niu, X; Wang, C; Zhou, F, 2021) |
| "Chronic neuropathic pain is a burden to millions of patients every day." | ( Bagdas, D; Damaj, MI; Gurdap, CO; Markwalter, PS; Neddenriep, B, 2019) |
| "Neuropathic pain is caused by the damage or dysfunction of the nervous system." | ( Wang, A; Xu, C, 2019) |
| "Neuropathic pain is a common type of chronic pain caused by trauma or chemotherapy." | ( Adamante, G; Bochi, GV; Chávez-Olórtegui, C; da Silveira Prestes, G; Dal-Toé De Prá, S; Dalenogare, DP; Damiani, AP; Ferro, PR; Machado-de-Ávila, RA; Milioli, AM; Moraes de Andrade, V; Pereira, AL; Rigo, FK; Trevisan, G, 2019) |
| "Neuropathic pain is frequently driven by ectopic impulse discharge (ectopia) generated in injured peripheral afferent neurons." | ( Devor, M; Yatziv, SL, 2019) |
| "Neuropathic pain is defined as pain caused by a lesion or a disease affecting the somatosensory nervous system." | ( Bégou, M; Bouchenaki, H; Demiot, C; Hajj, R; Magy, L, 2019) |
| "Neuropathic pain is a major incurable clinical problem resulting from peripheral nerve trauma or disease." | ( Andersen, OM; Bjerrum, OJ; Castonguay, A; De Koninck, Y; Enghild, JJ; Gonçalves, NP; Holm, TH; Login, H; Lorenzo, LE; Lykke-Hartmann, K; Malik, IJ; Nykjær, A; Pallesen, LT; Poulsen, ET; Richner, M; Rønn, LCB; Ulrichsen, M; Vægter, CB, 2019) |
| "Neuropathic pain is characterized by an uncertain etiology and by a poor response to common therapies." | ( Branca, JJV; Cialdai, F; Ciccone, V; Di Cesare Mannelli, L; Ghelardini, C; Lucarini, E; Micheli, L; Monici, M; Morbidelli, L; Pacini, A, 2019) |
| "Neuropathic pain is evoked by aberrant sensory processing in the peripheral or central nervous system, which is characterized by persistent pain, tactile allodynia, or hyperalgesia." | ( Chen, H; Chen, Y; Lian, N; Wang, Y; Xie, K; Yu, Y; Zhang, K, 2019) |
| "Neuropathic pain is a widespread and debilitating chronic pain and the treatment remains a clinical challenge." | ( Du, J; Liu, N; Ma, L; Niu, J; Sun, T; Yang, J; Yu, J; Zhang, G; Zhang, W; Zhu, C, 2019) |
| "Trigeminal neuropathic pain is seen as a huge clinical challenge." | ( Li, L; Wang, F; Yao, L; Zhang, Z, 2019) |
| "Neuropathic pain is a chronic and pathological pain caused by injury or dysfunction in the nervous system." | ( Baik, S; Choi, B; Han, SI; Hwang, H; Hyeon, T; Kim, D; Ko, G; Koo, S; Kwon, HJ; Lee, SJ; Manandhar, Y; Oh, J; Shin, K; Soh, M, 2019) |
| "Neuropathic pain is highly prevalent in pathological conditions such as diabetes, herpes zoster, trauma, etc." | ( Carcelén, M; de la Fuente, R; de la Puerta, R; Francés, R; Hurlé, MA; Tramullas, M, 2019) |
| "Neuropathic pain is a common pain condition that has a major negative impact on health-related quality of life." | ( Andersen, NT; Bach, FW; Carmland, ME; Finnerup, NB; Holbech, JV; Jensen, TS; Kreutzfeldt, M; Sindrup, SH, 2019) |
| "Neuropathic pain is rarely diagnosed." | ( Chen, Y; Lin, C; Ye, G; Yuan, L; Zhang, Y, 2019) |
| "Neuropathic pain is a complication after a spinal nerve injury." | ( Chen, H; Meng, X; Wang, Y; Xie, K; Yu, Y; Zhou, C, 2019) |
| "Neuropathic pain is a debilitating condition caused by the abnormal processing of somatosensory input." | ( Lee, KY; Prescott, SA; Ratté, S, 2019) |
| "Neuropathic pain is a disease caused by structural and functional plasticity in central and peripheral sensory pathways that produce alterations in nociceptive processing." | ( Giardini, AC; Kimura, LF; Lopes, FSR; Picolo, G; Sant'Anna, MB; Sant'Anna, OA, 2019) |
| "Neuropathic pain is associated with an increased sensitivity to painful stimuli or abnormal sensitivity to otherwise innocuous stimuli." | ( Choi, J; Choi, Y; Kim, JK; Kim, P; Kim, S; Kim, WJ; Lee, G; Lee, JH; Lee, JK; Lee, JS; Nam, YJ; No, KT; Song, MJ, 2020) |
| "Neuropathic pain is a chronic pain caused by central and peripheral nerve injury, long-term diabetes or treatment with chemotherapy drugs, and it is dissimilar to other chronic pain conditions." | ( Bán, EG; Brassai, A; Vizi, ES, 2020) |
| "Neuropathic pain is a severe disease caused by lesions or diseases in the somatosensory system." | ( Chen, C; Li, H; Pang, H; Ren, Y; Zheng, X, 2020) |
| "Neuropathic pain is partially refractory to currently available treatments." | ( Bao, YN; Dai, WL; Fan, JF; Li, SS; Liu, JH; Yu, BY; Zhao, WL, 2020) |
| "A core element of neuropathic pain is the loss of inhibitory tone in the spinal cord." | ( Caron, L; Costigan, M; Harney, D; Khuong, T; Larance, M; Littleboy, JB; Loo, L; Manion, J; Neely, GG; Ruan, T, 2020) |
| "Peripheral neuropathic pain is a common and disabling problem after traumatic brachial plexus injury with global plexopathy secondary to C5 rupture and avulsion of C6, C7, C8, and T1." | ( Monsivais, JJ, 2020) |
| "Neuropathic pain is clinically unsatisfactorily treated because of unclear mechanisms." | ( Dong, W; Jia, Q; Yang, X; Zhang, L, 2020) |
| "Central neuropathic pain is a common untreated symptom in progressive multiple sclerosis (PMS) and is associated with poor quality of life and interference with patients' daily activities." | ( Antoniazzi, CT; Dalenogare, DP; de Almeida, AS; Ferreira, J; Fialho, MFP; Kudsi, SQ; Lückemeyer, DD; Oliveira, SM; Pereira, GC; Pereira, VL; Ritter, C; Trevisan, G, 2020) |
| "Neuropathic pain is a chronic pain characterized by injury to the central or peripheral nervous system and that most often causes disability in individuals." | ( Elisei, LS; Galdino, G; Malta, IH; Moraes, TR, 2020) |
| "Neuropathic pain is defined as a direct consequence of an injury or disease that affects the somatosensory system, which may affect 7 to 10% of the world population." | ( Gestosa, SVS; Lares, AMG; Mulenas, NME; Ruivo, EFM, 2020) |
| "Neuropathic pain is a serious clinical problem to be solved." | ( Deng, Y; Kang, X; Li, G; Li, S; Wang, J; Wu, Z; Xie, Q; Yang, F; Yang, L; Zhang, G, 2020) |
| "Neuropathic pain is a kind of chronic pain that is triggered or caused primarily by damage to the nervous system and neurological dysfunction." | ( Chen, J; Chen, T; Chi, X; Deng, Y; Liu, P; Tan, F; Tian, J; Zheng, L, 2020) |
| "Neuropathic pain is a debilitating status that is insusceptible to the existing analgesics." | ( Chen, K; Hong, JH; Jia, P; Jin, XH; Liu, FF; Meng, FY; Shi, J; Wang, J; Zhang, T; Zhao, M, 2020) |
| "Neuropathic pain is a chronic condition which significantly reduces the quality of life and serious clinical issue that is in general resistant to available therapies." | ( Bogacka, J; Ciechanowska, A; Dobrogowski, J; Makuch, W; Mika, J; Pawlik, K; Popiolek-Barczyk, K; Przeklasa-Muszynska, A; Rojewska, E, 2020) |
| "Neuropathic pain is a major public health problem because it has a considerable impact on life quality of patients." | ( Han, J; Ling, D; Wang, Z; Wu, C; Zhao, Y, 2020) |
| "Neuropathic pain is usually persistent due to maladaptive neuroplasticity-induced central sensitization and, therefore, necessitates long-term treatment." | ( Chang, L; Li, F; Li, J; Lin, YH; Luo, CX; Wu, HY; Xu, C; Zhang, L; Zhang, Y; Zhang, YD; Zhu, DY, 2020) |
| "Treatment of neuropathic pain is still challenging." | ( Kwiatkowski, K; Makuch, W; Mika, J; Pawlik, K; Piotrowska, A; Rojewska, E; Wordliczek, J; Zajaczkowska, R, 2020) |
| "Chronic neuropathic pain is also linked with emotional disorders that aggravate the sensation of pain and which treatment has not been resolved." | ( Ferreira-Chamorro, P; Pol, O; Redondo, A; Riego, G, 2021) |
| "Chronic neuropathic pain is caused by tissue damage or nervous system inflammation and is characterized by sensitivity to painful stimuli." | ( Dan, Y; Guo, H; Guo, J; Li, G; Wu, B; Zheng, C, 2021) |
| "Neuropathic pain is a complex condition that is difficult to control and has a high impact on quality of life." | ( Barbosa, P; Gomes, A; Goncalves, D; Rebelo, V, 2020) |
| "Neuropathic pain is a multifaceted and ubiquitous disease across the globe." | ( Chen, J; Liu, P; Ma, S; Zhang, J; Zhou, J, 2021) |
| "Neuropathic pain is a critical burdensome problem due to the complex interplay of several pathological mechanisms and lack of availability of effective therapeutic interventions." | ( Belinskaia, DA; Deb, PK; Gadepalli, A; Shaw, S; Shestakova, NN; Tiwari, V; Uniyal, A; Venugopala, KN, 2020) |
| "Neuropathic pain is characterized by the presence of hyperalgesia and allodynia." | ( Déciga-Campos, M; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Moreno-Rocha, LA, 2021) |
| "Neuropathic pain is caused by a lesion or a functional impairment of the sensory nervous system and allodynia is one of the frequently observed symptoms in neuropathic pain." | ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Kiryu-Seo, S; Kiyama, H; Konishi, H; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ota, K; Sayo, A; Tomita, H, 2020) |
| "Chronic neuropathic pain is a condition that causes both sensory disturbances and a variety of functional disorders, indicating the involvement of various brain structures in pain pathogenesis." | ( Egorova, EL; Ermolenko, EV; Manzhulo, IV; Ponomarenko, AI; Starinets, AA; Tyrtyshnaia, AA, 2020) |
| "Many patients with neuropathic pain are not diagnosed or treated properly." | ( Andrade, DC; Baptista, AF; Barbosa, LM; Listik, C; Moisset, X; Nascimento, OJMD; Oliveira, RAA; Sá, KN; Teixeira, MJ, 2020) |
| "Neuropathic pain is a chronic debilitating condition caused by injury or disease of the nerves of the somatosensory system." | ( Amato, A; Di Giorgio, FP; di Matteo, A; Durando, L; Garrone, B; Milanese, C; Pistillo, L; Tongiani, S, 2021) |
| "PERSPECTIVE: Neuropathic pain is intractable in a clinical setting, and epigenetic regulation is considered to contribute to this processing." | ( Cheung, CW; Chung, SK; Fan, T; Gu, P; Pan, Z; Tai, WL; Wong, SSC, 2021) |
| "Ongoing neuropathic pain is one of the most challenging clinical problems which have detrimental effects on a patient's life quality." | ( Shantanu, PA; Tiwari, V; Vaidya, S, 2021) |
| "Pharmacotherapy of neuropathic pain is still challenging." | ( Bátai, IZ; Bölcskei, K; Dombi, Á; Kecskés, A; Kormos, V; Pintér, E; Pohóczky, K; Pozsgai, G; Sánta, C; Tékus, V, 2021) |
| "Neuropathic pain is common in the geriatric population." | ( Abrams, RMC; Pedowitz, EJ; Simpson, DM, 2021) |
| "Neuropathic pain is characterized by spontaneous painful symptoms." | ( Bioy, A; Cretineau, N; Etienne, R; Henry, A; Laurent, M; Salleron, J; Schohn, CH, 2021) |
| "Neuropathic pain is one of the foremost adverse effects that worsens quality of life for patients undergoing an antiretroviral treatment." | ( Allegue, C; Brea, J; Burgueño, J; Carracedo, Á; Cimadevila, M; Cruz, R; Domínguez, E; Loza, MI; Martínez, AL; Merlos, M; Monroy, X; Varela, MJ, 2021) |
| "Neuropathic pain is a chronic pain condition persisting past the presence of any noxious stimulus or inflammation." | ( Chia, JSM; Farouk, AAO; Hassan, NI; Mohamad, TAST; Perimal, EK; Sulaiman, MR; Zakaria, H, 2021) |
| "Neuropathic pain is a common chronic pain condition with major impact on quality of life." | ( Chen, GZ; Li, M; Luo, WJ; Wu, XZ; Yang, F; Zou, YQ, 2021) |
| "Neuropathic pain is a chronic condition with little specific treatment." | ( Chen, X; He, J; He, WY; Le, Y; Liu, KX; Wang, HB; Wang, YH; Xiong, QM; Zhang, L; Zheng, XQ, 2021) |
| "Neuropathic pain is a condition caused by a lesion or disease of the somatosensory nervous system." | ( Kamper, D, 2022) |
| "Neuropathic pain is still one of the unsolved public health problems worldwide." | ( Huang, C; Huang, Z; Jia, D; Liu, G; Sun, Y; Xue, M, 2021) |
| "Intractable neuropathic pain is a common symptom of neuromyelitis optica spectrum disorder (NMOSD)." | ( Beppu, S; Ishikura, T; Kinoshita, M; Koda, T; Kumanogoh, A; Kusunoki, S; Miyamoto, K; Mochizuki, H; Motooka, D; Murata, H; Okuno, T; Okuzaki, D; Shimizu, M; Shiraishi, N; Sugimoto, T; Sugiyama, Y; Tada, S; Yamashita, K; Yasumizu, Y, 2021) |
| "Neuropathic pain is a common chronic pain, which is related to hypersensitivity to stimulus and greatly affects the quality of life of patients." | ( Ahmad, KA; Chen, J; Ju, P; Ma, L; Wang, W; Wang, Y; Wei, J; Zhao, M, 2021) |
| "Neuropathic pain is a common complication of diabetes mellitus with poorly relieved by conventional analgesics." | ( Cao, XJ; Chen, X; Qian, HY; Sun, YZ; Wu, R; Xu, GY; Zhang, PA; Zhu, HY, 2021) |
| "Neuropathic pain is one of the most common conditions requiring treatment worldwide." | ( Chen, W; Ding, Y; Gou, Y; Hu, T; Lan, T; Li, Q; Liu, J; Ma, Y; Sun, Q; Wang, P; Yang, F; Zhang, Y, 2022) |
| "Neuropathic pain is a complex condition that usually lasts a lifetime and has a major negative impact on life after injury." | ( Song, T; Tao, X; Zhao, L, 2021) |
| "Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system." | ( Gossrau, G; Sabatowski, R, 2021) |
| "Neuropathic pain is a debilitating disease with few effective treatments." | ( Gao, SJ; Li, DY; Li, JY; Liu, DQ; Mei, W; Sun, J; Wu, JY; Zhang, LQ; Zhou, YQ, 2021) |
| "Neuropathic pain is a chronic pain state that negatively impacts the quality of life." | ( Khan, A; Khan, AU; Khan, S; Khan, SZ; Naveed, M; Rehman, ZU; Shal, B; Ullah, R, 2021) |
| "Neuropathic pain is a serious clinical issue, and its treatment remains a challenge in contemporary medicine." | ( Ciapała, K; Ciechanowska, A; Makuch, W; Mika, J; Pawlik, K; Rojewska, E, 2021) |
| "Neuropathic pain is a widespread health problem with limited curative treatment." | ( Cao, Z; He, J; Li, S; Tang, Q; Wang, Y; Xi, C; Zhao, F; Zhu, MX, 2022) |
| "Chronic neuropathic pain is particularly resistant to treatment, and patients often present after many failed therapies with multiple co-morbidities and complex medication histories." | ( Wren, KR, 2022) |
| "Neuropathic pain is a maladaptive pain phenotype that results from injury or damage to the somatosensory nervous system and is proposed to be linked to a cascade of events including excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation and apoptosis." | ( Areti, A; Arruri, VK; Gogoi, R; Komirishetty, P; Kumar, A; Sistla, R, 2021) |
| "Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety." | ( Du, J; Lan, XB; Li, YX; Liu, N; Liu, S; Ma, L; Tian, MM; Yang, JM; Yu, JQ; Zheng, P; Zhu, CH, 2021) |
| "Neuropathic pain is the most prevalent form of chronic pain caused by a disease of the nervous system, such as diabetic polyneuropathy." | ( Cassanego, G; De Freitas Bauermann, L; Rodrigues, P; Trevisan, G, 2022) |
| "Especially neuropathic pain is a significant clinical problem because there are few clinically effective drugs." | ( Inoue, K, 2022) |
| "Neuropathic pain is induced by segmental spinal nerve ligation (SNL), and inflammatory pain is induced by intraplantar injection of complete Freund's adjuvant (CFA)." | ( Bao, HG; Ge, C; Li, J; Liu, YX; Xu, C; Zhang, X; Zhao, Z; Zhu, YB, 2022) |
| "Neuropathic pain is an unbearable condition caused by nervous system damage." | ( Hirakawa, T; Igarashi, Y; Monde, K; Murai, Y; Sekiguchi, A; Usuki, S, 2022) |
| "Neuropathic pain is a debilitating chronic syndrome of the nervous system caused by nerve injury." | ( Hori, K; Ishikawa, T; Kwankaew, N; Okuda, H; Ozaki, N, 2022) |
| "Neuropathic pain is one of the common complications of diabetes." | ( Chen, Q; Cheng, K; Cheng, LZ; Jiang, AJ; Ma, JL; Wang, FJ; Yuan, HL; Zhou, JM, 2022) |
| "Neuropathic Pain is caused by damage to a nerve or disease of the somatosensory nervous system." | ( Bali, A; Jaggi, AS; Kaur, S; Singh, N, 2022) |
| "Neuropathic pain is a chronic pain caused by tissue injury or disease involving the somatosensory nervous system, which seriously affects the patient's body function and quality of life." | ( Chen, Z; Tan, B; Wu, X; Yu, J, 2022) |
| "Chronic neuropathic pain is a disabling condition that affects quality of life." | ( Assuncao, JP; Cardoso, C; de Castro, AM; Loureiro, MDC; Pinto, J; Vieira, IF, 2022) |
| "The etiology of neuropathic pain is complex, and the patients are distressed." | ( Chu, X; Huang, L; Jin, Q; Li, W, 2022) |
| "Neuropathic pain is chronic pain resulting from central or peripheral nerve damage that remains difficult to treat." | ( Du, J; Lan, X; Li, Y; Liu, N; Ma, H; Ma, L; Peng, X; Tian, M; Yang, J; Yu, J; Zheng, P; Zhu, C, 2022) |
| "Neuropathic pain is a refractory condition that involves de novo protein synthesis in the nociceptive pathway." | ( Cao, K; Chen, L; Duan, S; Gao, YJ; Gao, Z; Hu, Y; Ma, H; Mai, W; Sha, W; Wang, S; Wang, Y; Xu, ZZ; Zeng, LH, 2022) |
| "Neuropathic pain is still a challenge for clinical treatment as a result of the comprehensive pathogenesis." | ( Chen, G; Li, HY; Ling, ZM; Wang, Q; Wei, ZY, 2022) |
| "Neuropathic pain is one of the most important clinical consequences of injury to the somatosensory system." | ( Alves-Filho, JC; Arruda, LM; Buqui, GA; Cecilio, NT; Cunha, FQ; Cunha, TM; Dagostin, A; Davoli-Ferreira, M; Fernandes Gomes, FI; Fonseca, MD; Gonçalves, WA; Guimarães, RM; Huang, L; Kusuda, R; Leão, RM; Lemos, H; Lopes, AH; Lopes, NP; Maganin, AG; Mauriz Marques, LM; Mellor, A; Mendes, AS; O'Connor, JC; Pacholczyk, G; Sant'Anna, MB; Santana, DA; Santana-Coelho, D; Silva, CE; Silva, RL; Souza, GR; Talbot, J, 2022) |
| "Neuropathic pain is well known to occur after damage to the somatosensory system." | ( Pan, HC; Pan, LY; Sheehan, J; Sheu, ML; Yang, MY, 2022) |
| "Neuropathic pain is an important and disabling clinical problem, its management constitutes a challenge for healthcare professionals." | ( Alcántara Montero, A; Pacheco de Vasconcelos, SR, 2022) |
| "Neuropathic pain is a debilitating chronic disorder, significantly causing personal and social burdens, in which activated neuroinflammation is one major contributor." | ( Huang, CL; Lu, CC; Lu, YY; Tsai, HP; Wang, WT; Wu, CH; Zhang, ZH, 2022) |
| "Neuropathic pain is a pathological pain state with a broad symptom scope that affects patients after nerve injuries, but it can also arise after infections or exposure to toxic substances." | ( Alnouri, MW; Geisslinger, G; Hahnefeld, L; Hausch, F; Offermanns, S; Sisignano, M; Wedel, S, 2022) |
| "Neuropathic pain is a pathological pain state with a broad symptom scope that affects patients after nerve injuries, but it can also arise after infections or exposure to toxic substances." | ( Alnouri, MW; Geisslinger, G; Hahnefeld, L; Hausch, F; Offermanns, S; Sisignano, M; Wedel, S, 2022) |
| "Neuropathic pain is a pathological pain state with a broad symptom scope that affects patients after nerve injuries, but it can also arise after infections or exposure to toxic substances." | ( Alnouri, MW; Geisslinger, G; Hahnefeld, L; Hausch, F; Offermanns, S; Sisignano, M; Wedel, S, 2022) |
| "Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer." | ( Boden, A; Bourgouin, M; Caunes-Hilary, N; Fabre, A; Filleron, T; Lodin, S; Lusque, A; Mauries, V; Moreau, C; Mounier, M; Poublanc, M, 2022) |
| "Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer." | ( Boden, A; Bourgouin, M; Caunes-Hilary, N; Fabre, A; Filleron, T; Lodin, S; Lusque, A; Mauries, V; Moreau, C; Mounier, M; Poublanc, M, 2022) |
| "Neuropathic pain is a refractory chronic disease affecting millions of people worldwide." | ( Cai, S; Cheung, CW; Guo, W; Huang, Q; Li, F; Liu, JA; Shan, Z; Wang, Y; Yang, H, 2022) |
| "Neuropathic pain is a refractory chronic disease affecting millions of people worldwide." | ( Cai, S; Cheung, CW; Guo, W; Huang, Q; Li, F; Liu, JA; Shan, Z; Wang, Y; Yang, H, 2022) |
| "Neuropathic pain is a chronic pain condition that occurs after nerve damage; allodynia, which refers to pain caused by generally innocuous stimuli, is a hallmark symptom." | ( Ishibashi, T; Koga, K; Sueto, D; Tsuda, M; Yamaura, K; Yoshikawa, Y, 2022) |
| "Neuropathic pain is a condition affecting the quality of life of a substantial part of the population, but biomarkers and treatment options are still limited." | ( Anikanov, N; Baltin, M; Baltina, T; Efimova, O; Fedianin, A; Gorovaya, A; Khaitovich, P; Lebedev, MA; Petrova, D; Senko, D; Stekolshchikova, E; Tkachev, A, 2022) |
| "Neuropathic pain is one of the most critical types of chronic pain despite the increasing advances in medical science." | ( Akbarniakhaky, H; Dehpour, AR; Foroutani, L; Hemmati, S; Mohammadi, Z; Noori, T; Sadeghi, MA; Sheibani, M; Shirooie, S; Tavangar, SM; Yousefi-Manesh, H, 2023) |
| "Neuropathic pain is a subtype of chronic pain characterized by a primary lesion or dysfunction of the peripheral or central nervous system." | ( Esmaeili, M; Forouzanfar, F; Ghazavi, H; Mahdianpour, S; Pourbagher-Shahri, AM; Tanha, NK, 2023) |
| "Neuropathic pain is a disease that has become one of the major public health problems and a global burden." | ( Dai, Z; Jia, L; Liu, T; Ma, K; Qi, W; Si, J; Wang, R; Yin, J; Zhao, Y, 2023) |
| "Diabetic neuropathic pain is one of the microvascular complications of diabetes mellitus characterized by symmetrical pain and sensory abnormalities." | ( Baig, MW; Haq, IU; Khan, A; Khan, AU; Khan, S; Shal, B, 2023) |
| "Neuropathic pain is a chronic condition that causes long-term burning sensations." | ( Forouzanfar, F; Hajinejad, M; Negah, SS; Nemati, S; Roudbary, SMJM, 2023) |
| "Neuropathic pain is challenging to manage, and various drugs are required to control it, decreasing treatment adherence." | ( Hong, JH; Kang, SM; Ku, BJ, 2023) |
| "Neuropathic pain is a chronic pain owing to nerve damage or diseases of the central nervous system (CNS)." | ( Abbasi, Z; Baluchnejadmojarad, T; Farbin, M; Mehrabi, S; Roghani, M; Susanabadi, A, 2023) |
| "Neuropathic pain is a complex sort of pain that is detrimental to individuals' health, both physically and mentally, but merely a small portion of them could witness pain alleviation." | ( Duan, Y; Li, D; Lu, J; Tang, H, 2023) |
| "Neuropathic pain is a refractory disease with limited treatment options due to its complex mechanisms." | ( An, X; Chen, L; Chen, M; Chu, X; Gao, M; Li, Q; Li, R; Zhang, L; Zhu, X, 2023) |
| "Clinically, neuropathic pain is a severe side effect of oxaliplatin chemotherapy, which usually leads to dose reduction or cessation of treatment." | ( He, XH; Li, YD; Liu, CC; Shen, KF; Wang, J; Wu, W; Xu, LJ, 2023) |
| "OBJECTIVE: Neuropathic pain is regulated by several metabolites of the kynurenine pathway (KYNA-kynurenic acid, and QA-quinolinic acid)." | ( Debbag, S; Saricaoglu, F; Yalcinkaya, A, 2023) |
| "Neuropathic pain is a chronic pain caused by direct damage to the peripheral or central nervous system, characterized by hyperalgesia, allodynia, and spontaneous pain." | ( Liu, HZ; Miao, J; Su, DD; Wang, J; Wang, JL; Zhang, N; Zhang, YB, 2023) |
| "Neuropathic pain is highly prevalent in PD and negatively affects the quality of life of patients with PD." | ( Ishida, T; Kobayashi, Y; Koebis, M; Kogo, Y; Maeda, T, 2023) |
| "Neuropathic pain is a debilitating condition that affects millions of people worldwide." | ( Mika, J; Pawlik, K, 2023) |
| "Neuropathic pain is stubborn and associated with the peripheral nerve regeneration process." | ( Chen, S; Fang, Y; Li, L; Liao, Y; Tang, J; Wang, L; Zhang, T, 2023) |
| "Although neuropathic pain is a significant problem in polyneuropathy, the underlying molecular mechanisms are poorly understood." | ( Gerdle, B; Ghafouri, N; Lind, J; Stensson, N, 2022) |
| "Neuropathic pain is a common symptom experienced by most clinical diseases at different levels, and its treatment has always been a clinical difficulty." | ( Feng, X; Hu, JL; Liu, JP; Luo, HL; Xu, YS; Zhang, WJ; Zuo, C, 2023) |
| "Diabetic neuropathic pain is one of the complications that affect a wide variety of the diabetic population and is often difficult to treat." | ( Almeida-Leite, CM; de Assis Ferreira, LC; de Castro Junior, CJ; de Lima, ME; Mariano, XM, 2023) |
| "Neuropathic pain is differentiated from other types of chronic pain by abnormal sensory symptoms, such as shooting pain, burning pain, or numbness." | ( Raymond, TJ, 2023) |
| "Neuropathic pain is experienced due to injury to the nerves, underlying disease conditions or toxicity induced by chemotherapeutics." | ( Arthur, P; Kalvala, AK; Singh, MS; Surapaneni, SK, 2024) |
| "The treatment of neuropathic pain is challenging due to its heterogeneous etiologies, lack of objective diagnostic tools and resistance to classical analgesic drugs." | ( Thouaye, M; Yalcin, I, 2023) |
| "Neuropathic pain is a debilitating chronic pain condition and is refractory to the currently available treatments." | ( Chen, J; Fang, Q; Huang, H; Liu, X; Shi, Y; Wang, Y; Wu, W; Yao, M; Zeng, Y; Zhan, H; Zhang, X; Zhong, X, 2023) |
| "Neuropathic pain is a condition with varying origins, including reduced dietary micronutrient intake." | ( Amaral, MJD; Lima, LMTR; Martins, AF; Matias, DO; Miranda, ALP; Santos, BLR; Sisnande, T, 2023) |
| Excerpt | Reference |
|---|
| "The results show that neuropathic pain can respond to opioids and to systemically administered local anesthetic drugs." | ( Fields, HL; Reisner-Keller, LA; Rowbotham, MC, 1991) |
| "Patients had (a) neuropathic pain, (b) had failed or been ineligible for noninvasive treatments, and (c) obtained greater than 50% pain relief with intrathecal trial infusions of morphine sulfate or sufentanil citrate." | ( Covington, EC; Guthrey, DS; Hassenbusch, SJ; Stanton-Hicks, M; Walsh, JG, 1995) |
| "This suggests that some types of neuropathic pain may be treatable with N-type VSCC blockers." | ( Sakashita, Y; Yamamoto, T, 1998) |
| "ALE-0540 was tested in models of neuropathic pain and thermally-induced inflammatory pain, using two routes of administration, a systemic i." | ( Bian, D; Kamboj, R; Lee, DK; Ossipov, M; Owolabi, JB; Porreca, F; Riopelle, RJ; Rizkalla, G; Ross, GM; Tehim, A; Wegert, S, 1999) |
| "Mechanisms of neuropathic pain relief from lidocaine therapy are yet to be understood." | ( Chen, LL; Mao, J, 2000) |
| "First-line therapy for neuropathic pain may be either an older generation antidepressant such as amitriptyline or nortriptyline or the anticonvulsant gabapentin." | ( Watson, CP, 2000) |
| "Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer." | ( Härtel, B; Kalso, E; Tasmuth, T, 2002) |
| "The underlying mechanisms of neuropathic pain are poorly understood, and existing treatments are mostly ineffective." | ( Gold, MS; Kim, CS; Lai, J; Porreca, F; Treanor, J; Wang, R; Weinreich, D, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | ( Backonja, M; Glanzman, RL, 2003) |
| "Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0." | ( Davies, PS; Mohr, D; Reisner, L; Rowbotham, MC; Taylor, K; Twilling, L, 2003) |
| "The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses." | ( Davies, PS; Mohr, D; Reisner, L; Rowbotham, MC; Taylor, K; Twilling, L, 2003) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | ( Nicholson, BD, 2003) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "The development of treatments for neuropathic pain has been hindered by our limited understanding of the basic mechanisms underlying abnormalities in nociceptor hyperexcitability." | ( Alessandri-Haber, N; Dina, OA; Levine, JD; Parada, CA; Reichling, DB; Yeh, JJ, 2004) |
| "The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects." | ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Tu, D; Weaver, DF, 2005) |
| "Chronic neuropathic pain occurs in 10-15% of patients with neuroborreliosis and is difficult to treat." | ( Hofmann, H; Ring, J; Weissenbacher, S, 2005) |
| "A phase-2 human trial with chronic, neuropathic pain patients suggested that AJA could become a useful drug for treating this condition." | ( Burstein, S, 2005) |
| "Predictors of response to neuropathic pain treatment in patients with painful distal sensory neuropathies are lacking." | ( Barbano, RL; Dworkin, RH; Herrmann, DN; Pannoni, V; Pennella-Vaughan, J, 2006) |
| "Existing treatments for neuropathic pain deliver inadequate pain relief, unacceptable side effects, or both." | ( Hill, RG; Rice, AS, 2006) |
| "However, rats with neuropathic pain may be in a magnesium-deficient condition at the effector site, such that magnesium treatment can decrease neuropathic pain." | ( Hahm, KD; Han, SM; Jeong, SM; Lee, C; Leem, JG; Shin, JW, 2006) |
| "Diabetic neuropathic pain, an important microvascular complication in diabetes mellitus is recognised as one of the most difficult types of pain to treat." | ( Agrewala, JN; Chopra, K; Kulkarni, SK; Sharma, S, 2006) |
| "Treatment of neuropathic pain is an area of largely unmet medical need." | ( Caram-Salas, NL; Granados-Soto, V; Medina-Santillán, R; Reyes-García, G, 2006) |
| "In the spinal nerve ligation model of neuropathic pain, subcutaneous administration of morphine, oxycodone, methadone and l-methadone had antiallodynic effects in tests of mechanical and cold allodynia." | ( Kalso, E; Kontinen, VK; Kylänlahti, I; Lemberg, K; Viljakka, K; Yli-Kauhaluoma, J, 2006) |
| "Fourty six patients with neuropathic pain which was burning, stabbing and shooting in quality were allocated to take gabapentin (group GBP) and amitriptyline (group AMI) monotherapy." | ( Aydinli, I; Keskinbora, K; Pekel, AF, 2006) |
| "Treatment decisions for patients with neuropathic pain can be difficult." | ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Diabetic neuropathic pain, an important microvascular complication in diabetes mellitus, has been recognized as one of the most difficult types of pain to treat." | ( Chopra, K; Kulkarni, SK; Sharma, S, 2007) |
| "Forty patients with chronic neuropathic pain (23 male, 17 female) were treated with escalating dosages of CNS 5161." | ( Forst, T; Marcus, P; Pfützner, A; Schütte, K; Smith, T, 2007) |
| "Peripheral neuropathic pain is a common clinical problem with few existing treatments." | ( Chang, JW; Kim, J; Kim, SJ; Lee, B; Lee, H, 2007) |
| "The treatment of neuropathic pain is challenging, in part because of its multiple etiologies." | ( Codd, EE; Martinez, RP; Molino, L; Rogers, KE; Stone, DJ; Tallarida, RJ, 2008) |
| "The treatment of neuropathic pain is a major unresolved medical challenge." | ( Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007) |
| "We used a murine model of neuropathic pain induced by sciatic nerve constriction to study the antiallodynic properties of a chronic treatment with the tricyclic antidepressants nortriptyline and amitriptyline." | ( Barrot, M; Benbouzid, M; Freund-Mercier, MJ; Gavériaux-Ruff, C; Kieffer, BL; Muller, A; Tessier, LH; Waltisperger, E; Yalcin, I, 2008) |
| "Many treatments for neuropathic pain activate or augment norepinephrine release in the spinal cord, yet these treatments are less effective against acute nociceptive stimuli." | ( Clayton, BA; Eisenach, JC; Hayashida, KI; Johnson, JE, 2008) |
| "A number of drugs are used to treat neuropathic pain, including anticonvulsants and antidepressants." | ( Beydoun, A; Nasreddine, W, 2007) |
| "We present a patient with intractable neuropathic pain because of radiation-induced transverse myelitis unresponsive to medical treatment." | ( Haider, N; Hamid, B, 2007) |
| "The treatment of neuropathic pain is mainly based on antiepileptics, tricyclic antidepressants, and opiates." | ( Arnold, P; Deriaz, O; Gobelet, C; Kuntzer, T; Vuadens, P, 2008) |
| "Our patient is the first patient with neuropathic pain, treated with gabapentin who developed hemichorea, in the absence of brain lesions." | ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "After establishment of neuropathic pain induced by L5 and 6 spinal nerve transection (SNT), the sciatic nerve was treated with 2% capsaicin at the level of the midthigh." | ( Hwang, SJ; Kim, E; Kim, J; Kim, SM; Lee, SE; Shin, HK, 2008) |
| "They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e." | ( Dworkin, RH; Emir, B; Griesing, T; Murphy, K; Sharma, U; Stacey, BR, 2008) |
| "These data present a novel approach to neuropathic pain therapy." | ( Burns, LH; Guo, W; Largent-Milnes, TM; Vanderah, TW; Wang, HY, 2008) |
| "The treatment of pain, particularly neuropathic pain, is one of the therapeutic applications of cannabis and cannabinoids that is currently under investigation and that stimulates interest among clinicians and basic researchers." | ( Goicoechea García, C; Martín Fontelles, MI, 2008) |
| "Central neuropathic pain following lesions within the CNS, such as spinal cord injury, is one of the most excruciating types of chronic pain and one of the most difficult to treat." | ( Engel, S; Lee, BB; McLachlan, E; Wasner, G, 2008) |
| "The treatment of neuropathic pain with antidepressants has a long history." | ( Berman, K; Fishbain, D; Kajdasz, DK, 2006) |
| "Chronic neuropathic pain is a frequent, serious outcome of spinal cord injury (SCI) that is highly refractory to treatment." | ( Chen, Y; Oatway, MA; Weaver, LC, 2009) |
| "Patients with moderate to severe neuropathic pain, despite the use of various pharmacologic treatments prior to study entry, were enrolled (n = 409) and treated with CR oxycodone plus pregabalin (n = 169), CR oxycodone (n = 106), and pregabalin (n = 134)." | ( Colini Baldeschi, G; Gatti, A; Occhioni, R; Reale, C; Sabato, AF, 2009) |
| "Conversely, symptomatic treatments for neuropathic pain were withdrawn after few days because of side effects." | ( Camozzi, F; Ciano, C; Lauria, G; Lombardi, R; Penza, P, 2009) |
| "Chronic neuropathic pain is inadequately treated using current therapies, with less than half of patients achieving clinically significant pain relief (defined as more than 50% pain reduction)." | ( Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS, 2009) |
| "Management of neuropathic pain remains problematic; however, cell therapy to treat the effects of pain on the sensory system after spinal cord injury (SCI) could be a useful approach." | ( Eaton, MJ; Wolfe, SQ, 2009) |
| "To this purpose, in rats with neuropathic pain model of chronic constriction of one sciatic nerve (CCI rats), we administered methadone before or after opioid receptor blockade with naloxone and checked its effects on the spinal Wide Dynamic Range (WDR) neuron dynamics in three experimental conditions: on the spontaneous and noxious evoked neuronal activities in control rats (sham operated and naïve); on iontophoretic NMDA induced neuronal hyperactivity in intact rats; on pain-related spontaneous and noxious evoked hyperactivities in CCI rats." | ( Biella, GE; Caramenti, G; Sotgiu, ML; Storchi, R; Valente, M, 2009) |
| "Treating neuropathic pain remains a great challenge, and the treatment has to be individualized to the single patient, taking into account side effects, pain type, comorbidities, and drug interactions." | ( Finnerup, NB; Jensen, TS; Madsen, CS, 2009) |
| "Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy." | ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Jackson, AC; Tu, D, 2009) |
| "Chronic neuropathic pain is underrecognized and undertreated, yet primary care physicians are uniquely placed on the frontlines of patient management, where they can play a pivotal role in treatment and prevention through diagnosis, therapy, follow-up, and referral." | ( Backonja, MM; Baron, R; Bennett, MI; Bouhassira, D; Cruccu, G; Haanpää, ML; Hansson, PT; Jensen, TS; Kauppila, T; Rice, AS; Smith, BH; Treede, RD, 2009) |
| "A number of different treatments for neuropathic pain have been studied, but the literature is sizable, rapidly evolving, and lacks important information about practical aspects of patient management." | ( Dworkin, RH; O'Connor, AB, 2009) |
| "Treatment of neuropathic pain is a major clinical challenge that has been met with minimal success." | ( Asiedu, M; Kaila, K; Ossipov, MH; Price, TJ, 2010) |
| "Twenty patients with localized neuropathic pain [postoperative neuropathic pain (n = 14); complex regional pain syndrome (n = 2); and postherpetic neuralgia (n = 4)], who had been successfully treated with 5% lidocaine medicated plaster, were followed up by telephone interview after 3 and 5 years." | ( Griessinger, N; Likar, R; Sittl, R; Tzabazis, A; Wilhelm, IR, 2010) |
| "Current clinical treatments for neuropathic pain include amitriptyline, a tricyclic antidepressant with mixed pharmacology that is also clinically reported to impair cognitive performance; and gabapentin, a compound that selectively interacts with alpha2delta-1 calcium channel subunits." | ( Arneric, SP; Buccafusco, JJ; Snutch, TP; Terry, AV; Vazdarjanova, A, 2010) |
| "The concept that many neuropathic pain syndromes (traditionally this definition would include complex regional pain syndromes (CRPS)) are "sympathetically maintained pains" has historically led to treatments that interrupt the sympathetic nervous system." | ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| "Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment." | ( Bennett, GJ; Collet, JP; Ducruet, T; Gamsa, A; Huynh, T; Robinson, A; Shapiro, S; Wang, T; Ware, MA, 2010) |
| "In practice, when a patient with neuropathic pain requires local treatment, in the absence of a better alternative, it is better to use lidocaine plasters, which are better tolerated and with which we have more experience." | ( , 2010) |
| "The elusiveness of neuropathic pain mechanisms is a major impediment in developing effective clinical treatments." | ( Bazan, NG; Cui, JG, 2010) |
| "However, OXAL induces neuropathic pain which hampers the chemotherapy success." | ( Mensah-Nyagan, AG; Meyer, L; Patte-Mensah, C; Taleb, O, 2011) |
| "Current drugs to treat neuropathic pain, including anticonvulsivants and antidepressants, fail in up to 40-50% of the patients, while in the rest of them total alleviation is not normally achieved." | ( Ezquerra, L; Herradón, G; Martin, YB, 2011) |
| "Diabetic neuropathic pain is amongst the most difficult types of pain to treat mainly due to the lack of understanding of its etiology and inadequate relief with available drug therapy." | ( Chopra, K; Kuhad, A; Tiwari, V, 2011) |
| "We used the painDETECT neuropathic pain screening questionnaire to identify likely pain mechanisms in 343 patients with low back pain with or without leg pain in southeastern England referred for physiotherapy." | ( Beith, ID; Chestnut, TJ; Kemp, A; Kenyon, J; Prout, M, 2011) |
| "Understanding and consequently treating neuropathic pain effectively is a challenge for modern medicine, as unlike inflammation, which can be controlled relatively well, chronic pain due to nerve injury is refractory to most current therapeutics." | ( Costigan, M; Latremoliere, A, 2011) |
| "However, most patients with neuropathic pain have no chance to receive preemptive treatment and it remains unclear whether there is a therapeutic time window for post treatment with minocycline." | ( Mei, XP; Ren, J; Xie, C; Xu, H; Xu, LX; Zhang, H; Zhou, Y, 2011) |
| "Current treatments of neuropathic pain arising from conditions such as nerve injury/compression are only partially effective, and limited in their use by side-effects." | ( Anand, P; Baines, AJ; Bird, N; Chizh, BA; Lai, RY; Ostenfeld, T; Palmer, JE; Robertson, J; Shenoy, R, 2011) |
| "Severe chronic neuropathic pain is a challenge to treat, and due to adverse effects of classical oral medication, optimal and effective dose levels are difficult to reach." | ( Hesselink, JM; Kopsky, DJ, 2012) |
| "PNS is utilized to treat peripheral neuropathic pain." | ( Kobesova, A; Kolar, P; Kozak, J; Steindler, J; Vrba, I, 2011) |
| "Chronic neuropathic pain was induced by chronic constriction injury of the sciatic nerve, and subsequently a cannula was implanted in the PAG area for the purpose of electrical stimulation and intra-PAG drug administration." | ( Halder, S; Khanna, N; Mehta, AK; Sharma, KK; Tandon, OP, 2012) |
| "A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment." | ( Ciria, JP; Fernández, MC; Gonzálvez, ML; López-Gómez, V; Mańas, A; Masramon, X; Morillo, V; Pérez, M, 2011) |
| "It is argued that relief of neuropathic pain attributable to ARA290 treatment is related to its antiinflammatory properties, possibly within the central nervous system." | ( Aarts, L; Brines, M; Cerami, A; Dahan, A; Morariu, A; Niesters, M; Swartjes, M, 2011) |
| "The management of neuropathic pain is unsatisfactory, and new treatments are required." | ( Carr, FB; Géranton, SM; Hunt, SP; Liu, Q; Lumb, BM; Obara, I; Tochiki, KK, 2011) |
| "Medications used to treat neuropathic pain may provide relief." | ( Bruyère, PJ; Courtois, AC; Crielaard, JM; Douchamps, F, 2012) |
| "Diabetes-induced neuropathic pain is recognized as one of the most difficult type of pain to treat and conventional analgesics are well known to be partially effective or associated with potential toxicity." | ( Sharma, PL; Taliyan, R, 2012) |
| "Patients suffering from neuropathic pain are difficult to treat and many methods are used to resolve this issue." | ( Chung, SC; Liu, YC; Tsai, YC; Tseng, FL; Yeh, CY, 2011) |
| "Treatment of severe neuropathic pain with PR oxycodone/PR naloxone provided effective analgesia with the added benefit of favorable effects on bowel function and quality of life." | ( Hermanns, K; Junker, U; Nolte, T, 2012) |
| "When neuropathic pain is diagnosed, appropriate treatment is important in limiting the severe psychosocial impairment that can ensue with undertreated pain." | ( Pierce, DM; Shipstone, E, 2012) |
| "In particular, neuropathic pain appears to be persistent despite various treatment attempts." | ( Baastrup, C; Finnerup, NB, 2012) |
| "For difficult to treat neuropathic pain from cancer, adjuvant analgesics are often used with opioids." | ( Kajiume, T; Karakawa, S; Kawaguchi, H; Kobayakawa, M; Kobayashi, M; Nakanuno, R; Ogura, T; Oshita, K; Sato, T; Sera, Y; Taguchi, S, 2012) |
| "It has been reported that <50% of neuropathic pain patients are satisfactorily treated with drugs." | ( Miyazaki, R; Yamamoto, T, 2012) |
| "Diabetes induced neuropathic pain is recognized as one of the most difficult types of pain to treat with conventional analgaesics." | ( Sharma, PL; Taliyan, R, 2012) |
| "In the neuropathic pain model, spinal administration of milnacipran clearly reduced the basal C-fibre-evoked FPs." | ( Kato, A; Ogawa, K; Ohnami, S; Ono, H; Shinohara, S; Tanabe, M, 2012) |
| "This work shows that inflammatory and neuropathic pain have much in common, and suggests that selective blockers of HCN2 may have value as analgesics in the treatment of pain." | ( Emery, EC; McNaughton, PA; Young, GT, 2012) |
| "Also described is neuropathic pain and refractory pain, coadjuvant treatments and non pharmacological analgesic treatments." | ( Borrega, P; Cassinello, J; Escobar, Y; Virizuela, JA, 2012) |
| "We administered ketamine when neuropathic pain in patients with advanced cancer became refractory to opioids and oral adjuvant analgesics." | ( Matsuda, Y; Ohno, Y; Okamoto, Y; Tanimukai, H; Tsugane, M; Tsuneto, S; Uejima, E, 2013) |
| "Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch." | ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "In WT mice, the main neuropathic pain symptoms induced by nerve injury were significantly reduced in a time-dependent manner by treatment with CO-RMs or CoPP." | ( Hervera, A; Leánez, S; Motterlini, R; Negrete, R; Pol, O, 2012) |
| "Relieving effects of nicotine on neuropathic pain were reversed by co-administration of mecamylamine (20nmol), a non-selective antagonist for nAChRs." | ( Fukazawa, Y; Kiguchi, N; Kishioka, S; Kobayashi, Y; Maeda, T; Nakamura, J; Ozaki, M; Tominaga, S, 2012) |
| "Peripheral neuropathic pain is a serious side effect of paclitaxel treatment." | ( Abe, K; Chiba, T; Hama, T; Katagiri, N; Kawakami, K; Saduka, M; Taguchi, K; Utsunomiya, I, 2012) |
| "After inducing of neuropathic pain by CCI, treatment with 25 and 50 mg/kg of naringenin and 10 mg/kg of pregabalin was given." | ( Bhutada, P; Harle, U; Jain, D; Kaulaskar, S; Rahigude, A, 2012) |
| "At present, unsatisfactory treatment of neuropathic pain will seek alternative targets for new drugs and it is possible that anti-inflammatory factors like IL-10, IL-4, IL-1alpha, TGF-beta 1 would fulfill this role." | ( Mika, J; Popiolek-Barczyk, K; Przewlocka, B; Rojewska, E; Zychowska, M, 2013) |
| "Analgesic treatment of peripheral neuropathic pain with the capsaicin 8% cutaneous patch is safe and effective." | ( Heskamp, ML; Maihofner, C, 2013) |
| "Multifactor neuropathic pain is one of the most frequent symptoms in AIDS patients and analgesic treatment is primarily based on the use of drug combination of opioids, tricyclic antidepressants and antiepileptics." | ( Cannata, F; Canneti, A; Di Marco, P; Luzi, M; Pasqualitto, F; Reale, C; Spinoglio, A, 2013) |
| "Patients (N = 75) with oncological neuropathic pain, previously untreated with pregabalin, were recruited in 5 Italian institutions between 2007 and 2010." | ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Treating neuropathic pain is a major clinical challenge, and the underlying mechanisms of neuropathic pain remain elusive." | ( Huang, ZJ; Liu, S; Liu, YP; Song, AA; Song, XJ; Zhang, YK, 2013) |
| "Chemotherapy-induced neuropathic pain (CNP) is the major dose-limiting factor in cancer chemotherapy." | ( Fei, Z; Huang, G; Ji, XT; Jia, D; Li, JM; Li, XK; Niu, L; Qian, NS; Wang, P; Zhang, L; Zhang, T; Zhao, DS, 2013) |
| "Chemotherapy-induced neuropathic pain is particularly resistant to currently available treatments." | ( Cesar-Rittenberg, P; Hohmann, AG; Lynch, ME, 2014) |
| "Cancer-related neuropathic pain is common; it can be disease related or related to the acute or chronic effects of cancer treatment." | ( Fallon, MT, 2013) |
| "After administration of standard neuropathic pain medication, pain was relieved in most patients." | ( Shi, X; Yu, S, 2013) |
| "In patients who have neuropathic pain refractory to traditional treatment options or, rather, decline traditional treatment options, statin therapy may be helpful." | ( Gillon, JT; Lowden, MR; Smith, SE, 2013) |
| "Patients from a previous study of neuropathic pain (NP) in the Spanish primary care setting still had symptoms despite treatment." | ( Blanco Tarrio, E; Gálvez Mateos, R; López Gómez, V; Pérez Páramo, M; Zamorano Bayarri, E, 2013) |
| "A potential new way of treating chronic neuropathic pain is to target specific pain-processing neurons based on their expression of particular receptor molecules." | ( Anderson, EM; Bokrand-Donatelli, Y; Caudle, RM; Mustafa, G; Neubert, JK, 2013) |
| "Because the treatment and management of neuropathic pain are extremely complicated, the characterization of novel analgesics and neuroprotectors with safe toxicological profiles is a crucial need to develop efficient therapies." | ( Mensah-Nyagan, AG; Meyer, L; Patte-Mensah, C; Taleb, O, 2014) |
| "Pregabalin reduced neuropathic pain due to SCI over a 12 to 16 week treatment period." | ( Emir, B; Juhn, M; Parsons, B; Sanin, L; Yang, R, 2013) |
| "The concept that many neuropathic pain syndromes (traditionally this definition would include complex regional pain syndromes (CRPS)) are "sympathetically maintained pains" has historically led to treatments that interrupt the sympathetic nervous system." | ( Cole, P; Derry, S; Moore, RA; Straube, S, 2013) |
| "Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage or disease of the somatosensory nervous system, and remains largely untreatable." | ( Costa, B; Della Valle, MF; Facci, L; Fusco, M; Giusti, P; Skaper, SD; Zusso, M, 2014) |
| "In a neuropathic pain model the chronic oral administration of BCP attenuated thermal hyperalgesia and mechanical allodynia, and reduced spinal neuroinflammation." | ( Gertsch, J; Klauke, AL; Markert, A; Pradier, B; Racz, I; Zimmer, A; Zimmer, AM, 2014) |
| "Recent evidence of neuropathic pain among adults with sickle cell disease (SCD) reveals a need for adjuvant analgesic treatments for these patients." | ( He, Y; Molokie, RE; Suarez, ML; Wang, ZJ; Wilkie, DJ; Wittert, H; Yao, Y; Zhao, Z, 2014) |
| "One of its consequences is neuropathic pain which is often chronic and difficult to treat." | ( Barrot, M; Choucair-Jaafar, N; Freund-Mercier, MJ; Salvat, E, 2014) |
| "Central neuropathic pain (CNP) is a debilitating consequence of central nervous system damage for which current treatments are ineffective." | ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| "Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a challenging clinical issue." | ( Guo, Z; Hao, J; Jin, H; Man, Y; Mi, W; Su, X; Sun, X; Wang, X, 2014) |
| "In patients with neuropathic pain, topical forms of both capsaicin and lidocaine have been shown to be useful in the treatment of postherpetic neuralgia and diabetic peripheral neuropathic pain." | ( Galluzzi, KE; Stanos, SP, 2013) |
| "Treatment for chronic non-cancer neuropathic pain can be complicated by side effects and drug interactions." | ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| "Chemotherapy-induced neuropathic pain (CNP) is the major dose-limiting factor in cancer chemotherapy." | ( Chen, JH; Huang, BQ; Li, L; Lin, GA; Liu, H; Liu, JD; Pan, HT; Xie, HQ; Yang, Y; Zhang, N; Zhang, YG, 2014) |
| "Chronic neuropathic pain following surgery represents a serious worldwide health problem leading to life-long treatment and the possibility of significant disability." | ( Andersen, K; Balducci, A; Hitchens, TK; Janjic, JM; Patel, SK; Pollock, JA; Vasudeva, K; Zeyzus-Johns, B, 2014) |
| "The management of neuropathic pain is still a major challenge because of its unresponsiveness to most common treatments." | ( Chang, R; Guo, Q; Huang, C; Li, Q; Song, Z; Yang, D; Zhu, X, 2014) |
| "Taking pregabalin for the treatment of neuropathic pain poses an increased risk for developing ED in male patients." | ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "Antiepileptics used for treating neuropathic pain have various actions including voltage-gated Na(+) and Ca(2+) channels, glutamate-receptor inhibition, and GABA(A)-receptor activation, while local anesthetics are also used to alleviate the pain." | ( Fujita, T; Hirakawa, N; Kumamoto, E; Ohtsubo, S; Sakaguchi, Y; Uemura, Y, 2014) |
| "Pain caused by nerve injuries (neuropathic pain) is extremely difficult to treat." | ( Cui, Y; Donica, CL; Gutstein, HB; Shi, S, 2014) |
| "Treatment of neuropathic pain with opioid analgesics remains controversial and a major concern is the risk of addiction." | ( Cui, Y; Li, Y; Liu, X; Na, X; Pang, R; Wei, X; Wu, Y; Xin, W; Zang, Y; Zhou, L, 2014) |
| "Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury." | ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014) |
| "We obtained complete control of neuropathic pain after 6 months of the patients' evolution, preserving the function of the lingual nerve in all 3 neurolysis, without causing any impact as regards to the sensitive situation before treatment." | ( Gandara-Rey, JM; Garcia-Garcia, A; Perez-Sayans, M; Somoza-Martin, M, 2014) |
| "The therapy of neuropathic pain may include the use of co-analgesics, such as antidepressants, however, their desired analgesic effect is associated with significant side effects." | ( Jagla, G; Makuch, W; Mika, J; Obara, I; Przewlocka, B; Wordliczek, J, 2014) |
| "Among patients with acute neuropathic pain for whom additional opioids raises respiratory-related concerns, the use of dexmedetomidine should be considered as a viable treatment alternative." | ( O'Neil, T; Rodgers, PE; Shultz, C, 2014) |
| "Those patients who reported neuropathic pain were randomly treated with gabapentin or pregabalin." | ( Comoglu, SS; Dolgun, H; Gurer, B; Kertmen, H; Sekerci, Z; Turkoglu, E; Yilmaz, ER, 2014) |
| "The treatment of neuropathic pain challenges not only doctors but also hand therapists, since a majority of patients don't experience a significant pain relief despite systemic pain treatment." | ( Ammann, B; Oberfeld, E; Vögelin, E, 2014) |
| "Chronic neuropathic pain develops in approximately 40% of people after a spinal cord injury (SCI) and is notoriously difficult to treat." | ( Felix, ER, 2014) |
| "Chronic neuropathic pain is often refractory to standard pharmacological treatments." | ( Almog, S; Eisenberg, E; Ogintz, M, 2014) |
| "Many agents have been used to treat neuropathic pain but not all neuropathic conditions respond similarly to treatment." | ( Cho, SR; Diamond, I; Gould, HJ; Hernandez, C; Paul, D; Soignier, RD; Taylor, BK, 2014) |
| "HIV sensory neuropathy and distal neuropathic pain (DNP) are common, disabling complications associated with combination antiretroviral therapy (cART)." | ( Bloss, C; Clifford, DB; Collier, AC; Ellis, RJ; Franklin, D; Gelman, BB; Grant, I; Holzinger, E; Hulgan, T; Jia, P; Kallianpur, AR; Letendre, S; Marra, CM; McArthur, JC; McCutchan, JA; Morgello, S; Murdock, DG; Rosario, D; Samuels, DC; Simpson, DM; Wen, W; Zhao, Z, 2014) |
| "Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of patients respond differently to treatment." | ( Bouhassira, D; Choy, E; Cruccu, G; Freynhagen, R; Kosek, E; Lledó, A; Marchettini, P; Micó, JA; Perrot, S; Schacht, A; Skljarevski, V; Spaeth, M; Tesfaye, S; Tölle, T; Wilhelm, S, 2014) |
| "We are reporting on four patients with neuropathic pain syndromes successfully treated with a capsaicin 8% patch in the affected area of the head or face." | ( Gaul, C; Resch, S, 2015) |
| "Treatment with lacosamide in neuropathic pain due to different causes could be considered an effective and well-tolerated alternative for patients who fail to respond to standard treatments." | ( Almajano, J; Aragón, E; Bermejo, PE; Blanco, MV; Ceballos, MÁ; Colás, J; Costa-Frossard, L; García del Carrizo, F; Gómez-Argüelles, JM; Lara, M; Latorre-González, G; Morin-Martin, Mdel M; Sánchez-Del Valle, O; Toribio-Díaz, ME; Valenzuela-Rojas, FJ, 2014) |
| "Eighteen patients with postthoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain." | ( Benedetti, F; Finnerup, NB; Grosen, K; Jensen, TS; Petersen, GL; Pilegaard, HK; Price, DD; Tracey, I; Vase, L, 2014) |
| "Recent understanding of neuropathic pain pathophysiology suggests that multiple mechanisms, both at the peripheral and the central nervous system levels, underlie neuropathic pain, pointing to the possibility that targeting multiple mechanisms simultaneously can improve treatment outcome." | ( Eisenberg, E; Suzan, E, 2014) |
| "The induction of neuropathic pain following L5-L6 spinal nerve ligation (SNL) resulted in robust mechanical and cold allodynia and heat hyperalgesia in both sham and OB vehicle-treated animals." | ( Burke, NN; Finn, DP; Roche, M, 2015) |
| "The morphine tolerance model in neuropathic pain was established by repeated administration of morphine twice daily (10 mg/kg s." | ( Du, D; Jiang, W; Wang, J; Yu, T; Zhang, X, 2015) |
| "Peripheral nerve injury can result in neuropathic pain, a chronic condition of unclear cause often poorly responsive to current treatments." | ( Chen, X; Dai, D; Lu, Y; Wang, G; Yuan, L; Zhang, A; Zhang, P, 2014) |
| "No differences were seen in the neuropathic pain questionnaire values at any time point during treatment between the three groups." | ( De Vooght, P; Heylen, R; Kozicz, T; Mestrum, R; Puylaert, M; Roubos, E; Van Zundert, J; Vanelderen, P; Vissers, K, 2015) |
| "The treatment of neuropathic pain is a medical challenge." | ( Chiarlone, R; Fogliardi, A; Intelligente, F; Irace, C; Lanzilotta, M; Lattanzi, S; Palomba, R; Provinciali, L; Storelli, E; Zampi, M, 2014) |
| "However, recognition and treatment of neuropathic pain is also important." | ( Calabek, B; Callaghan, B; Feldman, EL, 2014) |
| "Its usefulness for treating central neuropathic pain is likely to be limited." | ( Barber, JK; Bombardier, CH; Brooks, L; Chiodo, AE; Fann, JR; Heinemann, AW; McCullumsmith, C; Richards, JS; Tate, DG; Temkin, NR; Wilson, CS, 2015) |
| "Treatments for neuropathic pain are either not fully effective or have problematic side effects." | ( Dickenson, AH; Friend, LV; Gonçalves, L, 2015) |
| "Treatment of neuropathic pain (NP) is a serious medical problem." | ( Abusueva, BA; Evzelman, MA; Kamchatnov, PR; Volkov, AI, 2014) |
| "Effective treatment of neuropathic pain without unacceptable side effects is challenging." | ( Colvin, LA; Fallon, MT; Fleetwood-Walker, SM; Krishan, A; Mitchell, R; Scott, AC; Storey, DJ; Weir, CJ, 2015) |
| "In a diabetic neuropathic pain model, pretreatment with celecoxib, L-NIL and 7-Ni, significantly increased the antihyperalgesic activity of both Met-F-AEA and AM 1241." | ( Bujalska-Zadrożny, M; de Cordé, A; Pawlik, K, 2015) |
| "Monotherapy with first-line drugs for neuropathic pain often fails to provide sufficient pain relief or has unacceptable side effects because of the need for high doses." | ( Bach, FW; Brøsen, K; Finnerup, NB; Holbech, JV; Jensen, TS; Sindrup, SH, 2015) |
| "Chemotherapy-induced neuropathic pain is one of the major problems for cancer patients." | ( Abed, A; Naji-Esfahani, H; Pilehvarian, AA; Rafieian-Kopaei, M; Safaeian, L; Vaseghi, G, 2016) |
| "Patients with neuropathic pain resulting from lumbosciatalgia were assigned to conventional treatment plus PEA or conventional treatment." | ( Jaen, A; Morera, C; Sabates, S, 2015) |
| "PAIN ETIOLOGY: Neuropathic pain seems to be the major pain etiology in cancer survivors and therefore adjuvant analgesics should be the first choice of analgesic treatment." | ( Kurita, GP; Sjøgren, P, 2015) |
| "Using a rat model of neuropathic pain, we evaluated the effect of pretreatment with clonidine-which has been shown to relieve intradermal capsaicin-induced hyperalgesia-on the initial hyperalgesic response and the thermal analgesic property of RTX." | ( Choi, SS; Choi, YS; Huh, BK; Hur, WS; Kim, HS; Kim, HZ; Lee, DK; Lee, MG; Lee, MK; Lim, BG, 2015) |
| "Chemotherapy-induced neuropathic pain is a significant side effect of chemotherapeutic agents." | ( Abdi, S; Kim, HK; Kwon, JY; Yoo, C, 2015) |
| "Chemotherapy-induced neuropathic pain was produced by intraperitoneal injection of PAC on 4 alternate days in male Sprague-Dawley rats." | ( Abdi, S; Kim, HK; Kwon, JY; Yoo, C, 2015) |
| "Diabetic neuropathic pain (DNP) is generally considered to be one of the most common complications of T2DM, which is also recognized as one of the most difficult types of pain to treat." | ( Cao, H; Fan, XF; Gong, YS; Li, J; Meng, B; Shen, LL; Shi, XT, 2015) |
| "Other types of neuropathic pain include post-herpetic neuralgia, trigeminal neuralgia, and neuralgia caused by chemotherapy." | ( Buggy, DJ; Butler, M; Gallagher, HC; Gallagher, RM; Henman, MC, 2015) |
| "In summary, the phenotype of neuropathic pain was associated with the efficacy of different pharmacologic treatments." | ( Lee, SH; Min, K; Oh, Y; Ryu, JS, 2016) |
| "Morphine is effective treatment for neuropathic pain but produces tolerance on chronic use." | ( Bedi, O; Deshmukh, R; Kaur, G; Kumar, P; Sharma, N; Singh, S, 2016) |
| "A selection of patients with neuropathic pain were treated off-label with one of four EGFR-Is, approved for the treatment of cancer." | ( Cameron, MG; Kersten, C; Laird, B; Mjåland, S, 2015) |
| "Conventional pharmacotherapy for neuropathic pain responsed vary and side effects limited their compliance." | ( Chen, F; Chen, L; Chen, S; Duan, S; Gui, Y; Li, A; Tang, Y; Zhou, H, 2015) |
| "Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a clinical challenge." | ( Fang, Y; Ge, WH; Zhang, L; Zhou, HH; Zhou, QG, 2016) |
| "Chronic neuropathic pain represents a clinically challenging state with a poor response to current treatment options." | ( Gajavelli, S; Jergova, S; Sagen, J; Shekane, P; Varghese, MS, 2016) |
| "Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment." | ( Batterham, A; Brookes, ME; Eldabe, S, 2017) |
| "The pharmacotherapy for neuropathic pain includes gabapentin and tramadol, but these are only partially effective when given alone." | ( Aranda, N; Castillo, R; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Zanetta, P, 2016) |
| "The effects of diazepam or Ro5-4864 on neuropathic pain were completely blocked by pretreatment with a neurosteroid synthesis inhibitor, aminoglutethimide (AMG)." | ( Chen, SL; Liu, XG; Wei, XH; Zang, Y; Zheng, WH, 2016) |
| "Moreover, the prevalence of neuropathic pain refractory to treatment is about 1." | ( Alcántara-Montero, A; Sánchez-Carnerero, CI, 2016) |
| "Treatment with lacosamide in neuropathic pain of various etiologies could be considered as an effective alternative for patients who do not respond or not tolerate standard treatments." | ( Alcántara-Montero, A; Sánchez-Carnerero, CI, 2016) |
| "Thirty patients with neuropathic pain and phenotyped as CYP2D6 extensive metabolizers were treated with a single oral dose of 100 mg tramadol." | ( Coelho, EB; de Moraes, NV; Godoy, AL; Lanchote, VL; Lauretti, GR; Neves, DV, 2016) |
| "RA administration decreased neuropathic pain (antihyperalgesic effect) but did not cause any improvement in sciatic nerve tissues, either alone or in combination with chemokine antagonists." | ( Abdel Mola, AF; Balfas, MA; Fahmi, MK; Hamed, EA; Makhlouf, MM; Mohamed Farghaly, HS, 2016) |
| "Treatment of neuropathic pain and chemotherapy-induced peripheral neuropathy (CIPN) in patients with malignancy is often unsuccessful." | ( Solomon, LR, 2016) |
| "Using the cuff model of neuropathic pain in mice, we show that acute pregabalin administration at high dose has a transitory antiallodynic action, while prolonged oral pregabalin treatment leads to sustained antiallodynic action, consistent with clinical observations." | ( Barrot, M; Ceredig, RA; Daniel, D; Hawkes, RA; Kremer, M; Nexon, L; Salvat, E; Wurtz, X; Yalcin, I, 2016) |
| "Preclinical Research Neuropathic pain is particularly difficult to treat because of its diverse etiologies and underlying pathophysiological mechanisms." | ( Corona-Ramos, JN; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Medina-López, JR, 2016) |
| "The treatment of neuropathic pain remains a clinical challenge because of its unclear mechanisms and broad clinical morbidity." | ( Chen, L; Cheng, Z; Dai, W; Deng, X; Han, Y; Hu, L; Jiang, C; Li, J; Liu, W; Pan, C; Xu, L; Zhang, G, 2016) |
| "Concerning the neuropathic pain model, δ-CNTX-Pn1a, when intrathecally administered, reversed the hyperalgesia evoked by sciatic nerve constriction." | ( Borges, MH; Cordeiro, MN; de Lima, ME; Duarte, ID; Emerich, BL; Ferreira, RC; Figueiredo, SG; Pimenta, AM, 2016) |
| "Chronic neuropathic pain is a debilitating condition that remains difficult to treat." | ( Chen, H; Chen, SR; Hittelman, WN; Li, L; Pan, HL; Wen, L; Xie, JD, 2016) |
| "Chemotherapy-induced neuropathic pain is difficult to treat." | ( Abdi, S; Hwang, SH; Kim, HK; Kim, SH; Lee, SO, 2016) |
| "Peripheral neuropathic pain (PNP) associated with trauma is often refractory to treatment." | ( Alvi, S; Bhatia, A; Bril, V; Brull, RT; Davis, AM; Gandhi, R; Lau, J; Mahomed, N; Perruccio, A; Wijeysundera, D, 2016) |
| "The recommended pharmacotherapy for neuropathic pain includes the use of some antidepressants, such as tricyclic antidepressants (TCAs) (amitriptyline…) or serotonin and noradrenaline re-uptake inhibitors (duloxetine…), and/or anticonvulsants such as the gabapentinoids gabapentin or pregabalin." | ( Barrot, M; Kremer, M; Muller, A; Salvat, E; Yalcin, I, 2016) |
| "Therapeutic potential of agomelatine on neuropathic pain was suppressed with α-methyl-para-tyrosine methyl ester (an inhibitor of catecholamine synthesis), phentolamine (a nonselective α-adrenoceptor antagonist), and propranolol (a nonselective β-adrenoceptor antagonist) administrations." | ( Aydın, TH; Can, ÖD; Demir Özkay, Ü; Turan, N, 2016) |
| "Chemotherapy-induced neuropathic pain (CINP) remains a major unmet medical need." | ( Burstein, ES; Ma, JN; McFarland, K; Olsson, R, 2016) |
| "Pharmacotherapy of neuropathic pain involves the use of antiepileptic agents, antidepressants, and opioids that may lead to numerous adverse effects, particularly in elderly patients." | ( Dobrogowski, J; Kocot-Kępska, M; Mika, J; Przeklasa-Muszyńska, A; Wiatr, M, 2016) |
| "The patient presented with neuropathic pain in his right arm due to a cervical syrinx which was surgically treated by a shunt in 2003 with no clinical improvement." | ( Darie, I; Fischer, D; Proust, F; Rohmer-Heitz, I; Simon, A; Voirin, J, 2016) |
| "Refractory neuropathic pain treated by motor cortex stimulation may be considered in palliative situations, and secondary therapeutic failure offers only a few perspectives." | ( Darie, I; Fischer, D; Proust, F; Rohmer-Heitz, I; Simon, A; Voirin, J, 2016) |
| "Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a severe dose- and therapy-limiting side effect of widely used cytostatics that is particularly difficult to treat." | ( Angioni, C; de Bruin, N; Geisslinger, G; Hofmann, M; Hohman, SW; Ji, RR; Jordan, H; Kuzikov, M; Liu, D; Lu, R; Meyer Dos Santos, S; Park, CK; Parnham, MJ; Schäfer, SM; Schmidt, M; Scholich, K; Schreiber, Y; Sisignano, M; Suo, J; Woolf, CJ; Yekkirala, AS; Zhang, DD; Zimmer, B; Zinn, S, 2016) |
| "Systemic gabapentin neuropathic pain management carries side-effects ostensibly preventable by localized therapy." | ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Using 3 rat models of neuropathic pain of toxic (oxaliplatin/OXA), metabolic (streptozocin/STZ), and traumatic (sciatic nerve ligation/CCI [chronic constriction nerve injury]) etiologies, we investigated the antihypersensitivity effect of acute and repeated agomelatine administration." | ( Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E, 2017) |
| "Adult patients exhibiting peripheral neuropathic pain (Numeric Rating Scale (NRS) ≥4 and Douleur Neuropathique 4 (DN4)≥4) for at least 3 months and under stable analgesic treatment for at least 1 month will be included." | ( Chenaf, C; Duale, C; Dubray, C; Eschalier, A; Kerckhove, N; Mallet, C; Pereira, B, 2016) |
| "Increased duration of relief from neuropathic pain is associated with (1) higher total infused doses of ketamine; (2) prolonged infusion durations, although the rate of infusion does not appear to be a factor; and (3) coadministration of adjunct medications such as midazolam and/or clonidine that mitigate some of the unpleasant psychomimetic side effects." | ( Chen, L; Maher, DP; Mao, J, 2017) |
| "Multiple sclerosis (MS)-induced neuropathic pain deteriorates quality of life in patients but is often refractory to treatment." | ( Chen, CC; Chung, CY; Lee, CH; Liao, F; Wang, IC, 2017) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Although evidence of desvenlafaxine in neuropathic pain is scarce, it presents some interesting pharmacokinetic properties, as it is not substrate or have activity on P-glycoprotein, and have a metabolism which practically does not depend on cytochrome P450 system, which limits the risk of pharmacokinetic interactions and potential problems associated tolerability when administered with drugs that are CYP2D6 moderate or potent inhibitors or other substrates of this isoenzyme." | ( Alcantara-Montero, A, 2017) |
| "When he had transferred, his neuropathic pain had been treated with 150-mg pregabalin per day (75 mg twice a day); however, he still exhibited severe neuropathic pain with a Numeric Pain Rating Scale score of 7 to 8." | ( Chang, MC; Choi, EJ; Do, KH; Yang, HE, 2017) |
| "Forty-two patients with neuropathic pain refractory to conventional therapy were randomly assigned to receive oral methadone (n = 14), ketamine (n = 14), or methadone plus ketamine (n = 14) over a 3-month period." | ( Caumo, W; Dalmolin, GD; Ferreira, J; Godoy, MC; Menezes, MS; Rigo, FK; Rossato, MF; Silva, MA; Trevisan, G, 2017) |
| "Chemotherapy-induced peripheral neuropathic pain (CIPN) is a common and severe debilitating side effect of many widely used cytostatics." | ( Angioni, C; Geisslinger, G; Hohmann, SW; Lee, S; Offermanns, S; Scholich, K; Sisignano, M; Tunaru, S; Woolf, CJ, 2017) |
| "Peripheral mechanical neuropathic pain is a serious side effect of docetaxel chemotherapy for cancer." | ( Bian, D; Gao, N; Huang, K; Jiang, B; Wang, R; Zhai, Q, 2017) |
| "The treatment of neuropathic pain due to low-back (lumbosacral) radiculopathies, a common source of neuropathic pain, is challenging and often requires a multimodal therapeutic approach." | ( Baron, R; Birklein, F; Cegla, T; Freynhagen, R; Heskamp, ML; Kern, KU; Maier, C; Maihöfner, C; Rolke, R; Seddigh, S; Sommer, C; Ständer, S; Treede, RD, 2017) |
| "The use of topiceuticals in localized neuropathic pain associated with malignancy remain a valuable option with many advantages over systemic treatments." | ( Paisley, P; Serpell, M, 2017) |
| "A distinct acute, severe form of neuropathic pain, called insulin neuritis or treatment-induced painful neuropathy of diabetes (TIND), may also occur shortly after initiation of intensive glycemic control, with an incidence rate of up to 10." | ( Anaya, CJ; Enriquez, C; Jolivalt, CG; Marquez, A; Nicodemus, JM, 2017) |
| "Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage)." | ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Compared with nociceptive pain, neuropathic pain is a challenging diagnosis to make and successfully treat in children with cancer." | ( Bruera, E; Madden, K, 2017) |
| "Chronic pain, neuropathic pain, inflammatory pain, ozone therapy, interventional therapy, gabapentin, spared nerve injury, bee venom, complete Freud's adjuvant." | ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "Numerous interventions for neuropathic pain (NeuP) are available, but its treatment remains unsatisfactory." | ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "Patients with preoperative neuropathic pain also report poor pain control postoperatively, suggesting an opportunity to identify these patients and intervene with empiric neuropathic pain treatment." | ( Buchakjian, MR; Davis, AB; Pagedar, NA; Sciegienka, SJ; Sperry, SM, 2017) |
| "Antidepressants are used to treat neuropathic pain and although the detailed mechanisms of their effects are unclear, the descending noradrenergic inhibitory system might play an important role." | ( Ito, S; Obata, H; Saito, S; Suto, T, 2018) |
| "Opioids are recommended as treatment of neuropathic pain." | ( Qiu, TT; Wang, CL; Yang, DJ; Yuan, BY, 2017) |
| "Pre-administration also attenuated neuropathic pain symptoms." | ( Han, F; Ji, C; Li, X; Sun, D; Wang, H; Xu, Y; Yao, X; Zhang, H, 2017) |
| "Treatment of neuropathic pain in children is challenging, and requires a multimodal approach of pharmacologic, physical, and psychological therapies; however there is little evidence to guide practice." | ( Amaria, K; Brown, S; Campbell, F; Johnston, B; McGrath, P; Pehora, C; Watkins, J, 2016) |
| "Persistent and treatment-resistant neuropathic pain may be a prominent feature in hantavirus-associated peripheral neuropathy." | ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017) |
| "The treatment of neuropathic pain is very complex and there are few drugs approved for this purpose." | ( da Silva, ABF; de Sousa, AG; Honorio, KM; Lipinski, CF; Oliveira, AA; Oliveira, PR; Pereira, EB; Romero, RAF; Weber, KC, 2017) |
| "Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient." | ( Abramov-Sommariva, D; Kugler, EM; Marziniak, M; Neubauer, C; Schimrigk, S; Werner, G, 2017) |
| "Cancer-related neuropathic pain often responds poorly to standard pain treatments." | ( Kim, HG; Kim, WJ; Park, HS; Yoo, SH, 2017) |
| "Chemotherapy-induced neuropathic pain is a distressing and commonly occurring side effect of many commonly used chemotherapeutic agents, which in some cases may prevent cancer patients from being able to complete their treatment." | ( Blake, A; Chow, E; DeAngelis, C; Diaz, P; Lao, N; Malek, L; O'Hearn, S; Wan, BA, 2017) |
| "Pregabalin is a first-line agent for neuropathic pain treatment whose abuse liability remains controversial." | ( Bura, SA; Cabañero, D; Maldonado, R, 2018) |
| "Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a serious dose-limiting neurotoxic effect of cancer drug treatment." | ( Al-Mazidi, S; Alotaibi, M; Alzoghaibi, M; Chaudhary, A; Djouhri, L; Nedjadi, T, 2018) |
| "We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but responded dramatically to the addition of levorphanol." | ( Bruera, E; Mallipeddi, T; Ng, A; Reddy, A, 2018) |
| "Development of chemotherapy-induced neuropathic pain (CINP) compromises the use of chemotherapy and greatly impacts thousands of lives." | ( Chen, Z; Cuzzocrea, S; Doyle, TM; Esposito, E; Jacobson, KA; Janes, K; Little, JW; Luongo, L; Salvemini, D; Tosh, DK; Wahlman, C, 2018) |
| "Cancer-related neuropathic pain is sometimes unresponsive to multidrug treatment." | ( Akechi, T; Kataoka, T; Kimura, K; Kondo, Y; Naiki, T; Sakamoto, N; Sato, N; Sugiyama, Y; Tasaki, Y, 2018) |
| "Several guidelines for neuropathic pain management and various effective drugs are available; however, neuropathic pain remains undertreated." | ( Fernandes, HL; Gama, R; Loureiro, MC; Pereira, FC; Tenreiro Pinto, J, 2018) |
| "Ongoing neuropathic pain is difficult to treat." | ( Anderson, M; Chen, X; Chen, Z; Dong, X; Grenald, SA; Guan, Y; He, SQ; Raja, SN; Shu, B; Stephens, KE; Tiwari, V; Yang, F; Zhang, T; Zheng, Q, 2018) |
| "In patients with neuropathic pain, we also longitudinally assessed changes in CBF 3 months after treatment with duloxetine." | ( Amino, H; Beppu, M; Hirano, S; Iimori, T; Isose, S; Kojima, K; Kuwabara, S; Matsumoto, K; Misawa, S; Mukai, H; Nagashima, K; Omori, S; Sato, T; Sekiguchi, Y; Shibuya, K; Suichi, T; Takemoto, M; Uno, T; Watanabe, K; Yokote, K, 2018) |
| "To analyze the cost of peripheral neuropathic pain (PNP) treatment with pregabalin or gabapentin at therapeutic doses in routine clinical practice." | ( Navarro-Artieda, R; Perez-Paramo, M; Rejas-Gutiérrez, J; Sicras-Mainar, A, 2018) |
| "Early LCM administration suppressed neuropathic pain in CCD rats." | ( Huo, F; Wang, Y, 2018) |
| "Paclitaxel-induced neuropathic pain is a major dose-limiting side effect of paclitaxel therapy." | ( Duggett, NA; Flatters, SJL; Griffiths, LA; Pitcher, AL, 2018) |
| "The treatment of neuropathic pain resulting from nervous system malfunction remains a challenging problem for doctors and scientists." | ( Kwiatkowski, K; Mika, J, 2018) |
| "Chemotherapy-induced peripheral neuropathic pain is a major limiting factor affecting cancer patients." | ( Ba, X; Hao, Y; Jin, G; Luo, X; Peng, Y; Wang, J; Yang, S; Zhou, S, 2018) |
| "The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain." | ( Gadhe, CG; Jeong, KS; Kim, GH; Lee, JY; Lim, EJ; Lim, KS; Lim, SM; Pae, AN; Son, WS; Yang, HK, 2018) |
| "It has been shown that neuropathic pain can be treated with the combination of simultaneous transcranial direct current stimulation and the generation of the visual illusion that the patient retains control of the affected limbs." | ( Lopez-Carballo, J; Opisso, E; Rodriguez, N; Sbert, M; Soler, D, 2018) |
| "Since its main adverse effect is neuropathic pain resulting from chemotherapy‑induced peripheral neuropathy (CIPN), this drug is used to study the neurobiology of CIPN in rodents and to search for analgesics that could attenuate neuropathic pain symptoms - cold and tactile allodynia that develop in most of the oxaliplatin‑treated subjects." | ( Furgała, A; Sałat, K; Sałat, R, 2018) |
| "Chemotherapy-induced peripheral neuropathic pain is a major dose-limiting and therapy-limiting adverse effect that is particularly difficult to treat." | ( Chen, J; Wang, R; Wu, Y, 2019) |
| "Chemotherapy-induced neuropathic pain (CINP) is a common and debilitating side effect of cancer treatment." | ( Chen, Y; Wu, P, 2019) |
| "Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited." | ( Ariyoshi, K; Inoue, A; Kizawa, Y; Koyama, A; Matsuoka, H; Oyamada, S; Tagami, K, 2019) |
| "However, neuropathic pain, characterized by hypersensitivity to cold, emerges soon after treatment." | ( Awaga, Y; Hama, A; Hayashi, I; Magata, Y; Natsume, T; Ogawa, S; Okamoto, S; Shidahara, Y; Takamatsu, H; Yamoto, K, 2019) |
| "Chronic neuropathic pain has demonstrated that coexisting psychiatric disorders are associated with disability and poorer treatment outcomes." | ( Fan, S; Jiang, F; Liu, X; Liu, Y; Mao, P; Sun, Y; Wei, X; Yan, H; Yang, L; Yao, K; Yuan, W; Zhang, S, 2019) |
| "Pediatric neuropathic pain is caused by a spectrum of disorders that are generally challenging to treat." | ( Adams, TL; Anderson, A; Tham, SW; Windsor, RB, 2019) |
| "The specific impact of neuropathic pain and recommended neuropathic pain treatments on the hormonal and immune status of patients has been so far poorly explored." | ( Corcuff, JB; Corriger, A; Duclos, M; Lambert, C; Macian, N; Marceau, G; Pereira, B; Pickering, G; Roux, D; Sapin, V, 2019) |
| "As an intractable health threat, neuropathic pain is now a key problem in clinical therapy, which can be caused by lesions affecting the peripheral nervous systems." | ( Gao, Y; Li, Q; Liu, YG; Liu, ZX; Wang, XD; Yang, BL; Zhang, YL; Zheng, XB; Zhou, CF; Zhu, GC, 2019) |
| "Although current neuropathic pain treatment guidelines do not recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), whether NSAIDs can serve as a useful adjuvant to conventional multimodal therapy remains unclear." | ( Cheng, YT; Huang, YH; Lin, FS; Lin, WY; Sun, WZ; Yen, CT, 2019) |
| "Treatment to alleviate neuropathic pain is required." | ( Guo, J; Han, B; Jia, D; Wang, H; Zhang, L, 2019) |
| "Central neuropathic pain related to spinal cord injury is notoriously difficult to treat." | ( Berthiller, J; Brinzeu, A; Caillet, JB; Mertens, P; Staquet, H, 2019) |
| "Current drug treatment available for neuropathic pain (NP) provides meager and partial pain relief due to incomplete efficacy and dose-dependent adverse effect." | ( Gill, SBS; Gulati, M; Jyoti, J; Kumar, B; Kumar, S; Melkani, I; Panchal, S; Pandey, NK; Singh, A; Singh, SK; Subedi, B, 2019) |
| "TENS may be a viable treatment for neuropathic pain (NP) during pregnancy." | ( Caño Silva, V; Serrano Afonso, A, 2019) |
| "However, the treatment effect of neuropathic pain is far from satisfactory." | ( Hu, P; Ji, S; Jia, N; Wang, Y; Xu, X; Yuan, H, 2019) |
| "Chemotherapy-induced neuropathic pain (CINP) in both sexes compromises many current chemotherapeutics and lacks an FDA-approved therapy." | ( Braden, K; Chen, Z; Doyle, TM; Jacobson, KA; Salvemini, D; Samson, WK; Stockstill, K; Tosh, DK; Wahlman, C; Yosten, GL, 2020) |
| "The search for new ligands to treat neuropathic pain remains a challenge." | ( Condés-Lara, M; Espinosa De Los Monteros-Zuñiga, A; González-Hernández, A; Martínez-Lorenzana, G, 2019) |
| "Chemotherapy-induced neuropathic pain (CINP) is a serious side effect of chemotherapy." | ( Kim, WM; Kim, YO; Song, JA; Yoon, MH, 2020) |
| "The effects of current treatments for neuropathic pain are limited." | ( Fujita, S; Kobayashi, M; Mayahara, K; Motoyoshi, M; Noma, D; Zama, M, 2020) |
| "Chemotherapy-induced neuropathic pain is a serious adverse effect of chemotherapeutic agents." | ( Araldi, D; Ferrari, LF; Green, PG; Levine, JD, 2020) |
| "Available treatments for neuropathic pain have modest efficacy and significant adverse effects, including abuse potential." | ( Grace, PM; Kavelaars, A; Lacagnina, MJ; Li, J; Lorca, S; Ma, J; Odem, MA; Walters, ET, 2020) |
| "Central neuropathic pain is a common untreated symptom in progressive multiple sclerosis (PMS) and is associated with poor quality of life and interference with patients' daily activities." | ( Antoniazzi, CT; Dalenogare, DP; de Almeida, AS; Ferreira, J; Fialho, MFP; Kudsi, SQ; Lückemeyer, DD; Oliveira, SM; Pereira, GC; Pereira, VL; Ritter, C; Trevisan, G, 2020) |
| "Chronic use of morphine treatment for neuropathic pain leads to morphine-induced analgesic tolerance." | ( Bandegi, AR; Damghanian, F; Miladi-Gorji, H; Safakhah, HA, 2020) |
| "The Rac1 inhibitor can ameliorate neuropathic pain only when administrated in the maintenance phase." | ( Bai, X; Chen, X; Chen, Z; Han, Z; Huang, J; Nie, B; Ouyang, H; Zhang, S, 2020) |
| "But whether LA is effective in treating neuropathic pain remains unknown." | ( Chen, K; Hong, JH; Jia, P; Jin, XH; Liu, FF; Meng, FY; Shi, J; Wang, J; Zhang, T; Zhao, M, 2020) |
| "Therapies to treat chronic neuropathic pain and its associated comorbidities are limited." | ( Batallé, G; Cabarga, L; Pol, O, 2020) |
| "In C57BL/6 male mice with neuropathic pain caused by the chronic constriction of the sciatic nerve, we assessed the effects of intraperitoneal administration of A-ITC and P-ITC in (a) the mechanical allodynia, thermal hyperalgesia and thermal allodynia induced by nerve ligation; (b) the anxiety- and depressive-like behaviours linked with neuropathic pain; (c) glial activation and mitogen-activated protein kinases phosphorylation, and (d) expression of the antioxidant enzymes, heme oxygenase 1 (HO-1), NADPH quinone oxidoreductase1, and glutathione S-transferase mu-1 (GSTM1), and alpha-1 (GSTA1), in hippocampus and prefrontal cortex (PFC)." | ( Batallé, G; Cabarga, L; Pol, O, 2020) |
| "Diabetic neuropathic pain, an important microvascular complication of diabetes mellitus, characterized by allodynia and hyperalgesia, is recognized as one of the most difficult types of pain to treat." | ( Bansal, S; Chopra, K; Kuhad, A; Kumar, A; Singh, P, 2020) |
| "Chronic neuropathic pain poses a significant health problem worldwide, for which effective treatment is lacking." | ( Gao, KX; Gong, MZ; Ren, P; Sun, HT; Yu, C; Zhang, Y; Zhao, X, 2020) |
| "We retrospectively assessed peripheral neuropathic pain using the neuropathic pain screening questionnaire (NeP score) in 187 patients (58 men, 129 women) who were treated with mirogabalin." | ( Misawa, H; Nishida, K; Ozaki, T; Takei, Y; Takigawa, T; Tetsunaga, T; Tsuji, H; Yamane, K, 2020) |
| "We report a stroke patient with neuropathic pain after C7 nerve transfer who received combination treatment of transcutaneous electrical nerve stimulation(TENS) and pregabalin." | ( Li, X; Wang, X; Xia, P; Yang, T, 2021) |
| "Symptoms include neuropathic pain and sensory alterations-no effective treatments are currently available." | ( Alves, CQ; David, JM; Espírito-Santo, RF; Gama, KB; Juiz, PJL; Lauria, PSS; Santos, DS; Soares, MBP; Villarreal, CF, 2020) |
| "Treatment of neuropathic pain is still challenging." | ( Kwiatkowski, K; Makuch, W; Mika, J; Pawlik, K; Piotrowska, A; Rojewska, E; Wordliczek, J; Zajaczkowska, R, 2020) |
| "The sensations caused by neuropathic pain are debilitating and improved treatment regimens are sought in order to improve the quality of life of patients." | ( Angelopoulou, E; Glascow, N; Julian, T; Syeed, R; Zis, P, 2020) |
| "Currently, the treatments for neuropathic pain are, control of the underlying disease process, then focused on symptomatic relief with pharmacotherapy, topical analgesics, or other interventions." | ( Broussard, A; Carroll Turpin, MA; Cornett, EM; Ellis, S; Hall, OM; Kaye, AD; Lim, VM; Range, T, 2020) |
| "Effective treatment of neuropathic pain is challenging as its underlying mechanism remains largely unknown." | ( Hazama, K; Ikeda, K; Itano, Y; Nakatsuka, H; Ouchida, M, 2020) |
| "Chronic neuropathic pain is also linked with emotional disorders that aggravate the sensation of pain and which treatment has not been resolved." | ( Ferreira-Chamorro, P; Pol, O; Redondo, A; Riego, G, 2021) |
| "A frail 85-year-old woman with chronic neuropathic pain after hip surgery, not responding to treatment with acetaminophen and morphine patches." | ( El Houssein, L; Hollmann, MW; Kallewaard, J; Steegers, MAH; van Poelgeest, EP; Wartenberg, HCH, 2020) |
| "Chronic neuropathic pain often has a negative impact on the quality of life and is difficult to treat." | ( El Houssein, L; Hollmann, MW; Kallewaard, J; Steegers, MAH; van Poelgeest, EP; Wartenberg, HCH, 2020) |
| "Treatment of peripheral neuropathic pain with 8% capsaicin patch seem to be effective in the short and medium term, both in decreasing pain intensity and in reducing the painful area." | ( Barbosa, P; Gomes, A; Goncalves, D; Rebelo, V, 2020) |
| "Chemotherapy-induced neuropathic pain harms the quality of life patients." | ( Chen, Y; Du, K; Feng, X; Wu, W; Xie, H, 2020) |
| "Chemotherapy-induced peripheral neuropathic pain (CIPNP) often occurs in cancer patients treated with antineoplastic drugs." | ( Bachmann, T; Bekker, A; Li, Z; Liang, L; Mao, Q; Tao, YX; Wen, J; Wu, S; Yang, Y; Zheng, B, 2021) |
| "The current pharmacotherapy of neuropathic pain is inadequate as neuropathic pain involves varied clinical manifestations with multifactorial etiology, modulated by a cascade of physical and molecular events leading to different clinical presentations of pain." | ( Abbas, S; Ahmad, N; Akbar, S; Din, ZU; Farooq, U; Islam, NU; Raziq, N; Shahid, M; Subhan, F; Ullah, I, 2021) |
| "Chronic neuropathic pain animals were treated with intrathecal or locally pre-administered activin C or the vehicle." | ( Bi, LB; Chen, Y; Gu, JH; Huang, YK; Jiang, ZJ; Li, QY; Liu, XJ; Liu, Y; Lu, YG; Shen, JX; Wu, XM; Zhang, FM; Zhang, JB; Zhao, X, 2020) |
| "Activin C inhibits neuropathic pain by modulating TRPV1 channels, revealing potential analgesic applications in chronic neuropathic pain therapy." | ( Bi, LB; Chen, Y; Gu, JH; Huang, YK; Jiang, ZJ; Li, QY; Liu, XJ; Liu, Y; Lu, YG; Shen, JX; Wu, XM; Zhang, FM; Zhang, JB; Zhao, X, 2020) |
| "Cisplatin-induced peripheral neuropathic pain is a common adverse effect of chemotherapy." | ( Abdelhalim, A; Ahmad, W; Al-Harrasi, A; Altaf, N; Ghaffar, R; Halim, SA; Karim, N; Khan, A; Khan, I, 2021) |
| "We produced a chronic neuropathic pain model by partial sciatic nerve ligation in mice, analyzed their electroencephalogram (EEG) and electromyogram (EMG) using the SleepSign software, and evaluated the sleep condition of the pain model mice after administration of amitriptyline or MDL 100907." | ( Aoki, Y; Hattori, M; Horikawa, H; Ito, H; Takemura, Y; Yamazaki, M, 2020) |
| "Central neuropathic pain (CNP) is often refractory to available therapeutic strategies and there are few evidence-based treatment options." | ( Andrade, DC; Baptista, AF; Barbosa, LM; Listik, C; Moisset, X; Nascimento, OJMD; Oliveira, RAA; Sá, KN; Teixeira, MJ, 2020) |
| "In the paclitaxel-induced neuropathic pain model in mice, MP1104 reduced both mechanical and cold allodynia and unlike morphine, did not produce tolerance when administered daily for 23 days." | ( Alder, AF; Atigari, DV; Kivell, BM; Majumdar, S; Miller, JH; Paton, KF; Scouller, B; Uprety, R; Váradi, A, 2021) |
| "Current treatments for neuropathic pain have often moderate efficacy and present unwanted effects showing the need to develop effective therapies." | ( Borgonetti, V; Galeotti, N, 2021) |
| "First-line pharmacotherapy for neuropathic pain entails the use of systemic antidepressants and anticonvulsants." | ( Coderre, TJ; Fulas, OA; Laferrière, A; Shir, Y; Ware, DMA, 2021) |
| "Pharmacotherapy of neuropathic pain is still challenging." | ( Bátai, IZ; Bölcskei, K; Dombi, Á; Kecskés, A; Kormos, V; Pintér, E; Pohóczky, K; Pozsgai, G; Sánta, C; Tékus, V, 2021) |
| "Chemotherapy-induced neuropathic pain (CINP) is a severe adverse effect of platinum- and taxane-derived anticancer drugs." | ( Choi, W; Go, EJ; Jeong, D; Kim, M; Kim, YH; Lee, H; Park, CK; Son, DB; Suh, JW, 2021) |
| "When treating neuropathic pain in the elderly, it is important to consider patients' comorbidities and other medications to avoid drug-drug interactions and iatrogenic effects given the physiologic changes of drug metabolism in the elderly." | ( Abrams, RMC; Pedowitz, EJ; Simpson, DM, 2021) |
| "Although some patients with peripheral neuropathic pain experience rapid improvements with a single treatment of capsaicin 179 mg patch, some may require two or three treatments before an initial response is observed." | ( Argoff, C; Eerdekens, M; Engelen, S; Freynhagen, R; Perrot, S, 2021) |
| "Current oral treatments for neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) have limited clinical efficacy, and undesirable side-effects." | ( Anand, P; Privitera, R, 2021) |
| "Chronic post-surgical neuropathic pain is difficult to treat." | ( Das, B; McCrory, C; Mullins, CF; Rooney, A; Walsh, S, 2022) |
| "Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system." | ( Infantino, R; Locarini, P; Luongo, L; Maione, S; Mattia, C; Pastore, AL, 2021) |
| "Treatment of neuropathic pain (NP) resulting from nerve injury is one of the most complicated and challenging in modern practice." | ( An, K; Li, NQ; Peng, Z; Wan, L; Xu, WW, 2021) |
| "Based on a complicated mechanism, neuropathic pain has no efficient treatment so far." | ( Moini Zanjani, T; Sabetkasaei, M; Sahebi Vaighan, N; Zarei, M, 2022) |
| "Patients with neuropathic pain may benefit from treatment with cannabis-based medicines or medical cannabis (CBM/MC), particularly in terms of reduced use of gabapentin and fewer days admitted to hospitals, compared with propensity score matched controls." | ( Hjorthøj, C; La Cour, P; Nordentoft, M; Posselt, CM, 2022) |
| "Chemotherapy-induced neuropathic pain is a debilitating and common side effect of cancer treatment and so far no effective drug is available for treatment of the serious side effect." | ( Chen, JP; Chen, N; Ge, MM; Li, DY; Liu, DQ; Tian, YK; Wang, XM; Ye, DW; Zhou, YQ, 2021) |
| "Lidocaine administration reduced mean Neuropathic Pain Symptom Inventory paresthesia/dysesthesia scores when compared with placebo by 1." | ( Bakos, K; Bottros, M; Frey, K; Haroutounian, S; Kagan, L; Kraus, K; Lee, JB; Meacham, K; Rao, L; Swarm, RA; Tallchief, D; Todorovic, MS; Zang, X, 2021) |
| "Current pharmacotherapy of neuropathic pain has insufficient effectiveness, so comprehension of neuropathic pain mechanism is necessary for research of new therapeutic methods." | ( Olakowska, E; Sojka, P; Właszczuk, A, 2021) |
| "In conclusion, PCA can alleviate neuropathic pain of CCI rats, improve oxidative stress by inhibiting the JNK/CXCL1/CXCR2 signaling pathway, which provides a new perspective for the treatment of neuropathic pain caused by CCI." | ( Chang, HX; Zhao, YF, 2022) |
| "This study examined neuropathic pain and neurocognitive outcomes in survivors of childhood ALL treated with contemporary therapy on a clinical trial (NCT00137111)." | ( Alberts, NM; Anghelescu, DA; Conklin, HM; Jacola, LM; Krull, KR; Partanen, M; Pui, CH, 2022) |
| "Chronic neuropathic pain is particularly resistant to treatment, and patients often present after many failed therapies with multiple co-morbidities and complex medication histories." | ( Wren, KR, 2022) |
| "The fact that neuropathic pain (NP) has no effective therapy and is frequently accompanied by psychiatric comorbidities is well established." | ( Chen, C; Feng, X; Ke, J; Li, J; Liu, A; Liu, Y; Lu, Q; Luo, L, 2022) |
| "Treatment of LPA animals with the neuropathic pain drug amitriptyline reduced joint pain for over 2 hours with no sex differences being observed." | ( McDougall, JJ; Reid, AR, 2022) |
| "The behavior of neuropathic pain was assessed in DNP rats after intracerebroventricular administration of GLP-1RA or microglial inhibitor minocycline." | ( Bao, W; Ji, L; Li, Q; Li, Y; Liu, S; Liu, X; Lu, B; Sun, W; Xiong, Q; Yi, N; Zhang, Q; Zhang, S; Zheng, H; Zhu, X; Zuo, C, 2022) |
| "Among different types of chronic pain, neuropathic pain (NP), arising from damage to the nervous system, including peripheral fibers and central neurons, is notoriously difficult to treat and affects 7-10% of the general population." | ( Castro, L; Castro, M; Fang, CY; Neugebauer, V; Shen, CL; Sherali, S; Wang, R; White, S, 2022) |
| "Pregabalin is used in the treatment of neuropathic pain of various etiologies and as an adjuvant in epilepsy." | ( Chakrabarti, SS; Dhameja, N; Jaiswal, S; Kaur, U; Mohan, A; Rai, T; Yadav, V, 2022) |
| "Peripheral neuropathic pain was induced in the Sprague Dawley (SD) rats by administration of paclitaxel (4 mg/kg) and vincristine (200 µg/kg) on days 1, 3, 5, 7, and 9, respectively." | ( Ahsan Halim, S; Al-Harrasi, A; Ali, G; Khan, A; Rasheed, A; Subhan, F; Ullah, R, 2022) |
| "Chemotherapy-induced neuropathic pain is a major clinical problem with limited treatment options." | ( Li, D; Lin, SY; Liu, M; Lv, YY; Xin, WJ; Xiong, YC; Xu, T; Zhao, YT, 2022) |
| "Currently available treatments for neuropathic pain are only modestly efficacious when assessed in randomized clinical trials and work for only some patients in the clinic." | ( Chiodo, V; De Guzman, R; Frazer, ME; Geha, P; Gewandter, JS; Markman, JD; Sharma, S; Sohn, MB, 2022) |
| "Acupuncture is a treatment for neuropathic pain, but its mechanism remains unclear." | ( Dai, QX; Li, S; Lin, FH; Mo, YC; Ni, XQ; Ren, M; Wang, JL; Wu, X; Yao, XY, 2022) |
| "Currently available treatments for neuropathic pain have limited efficacy in most patients." | ( Hara, K; Haranishi, Y; Terada, T, 2022) |
| "Mice with chronic neuropathic pain also showed disrupted NREM and total sleep that was normalized by systemic administration of two structurally different KOR antagonists, norbinaltorphimine and NMRA-140, currently in phase II clinical development, or by CRISPR/Cas9 editing of paraventricular nucleus KOR, consistent with endogenous KOR activation disrupting sleep in chronic pain." | ( Dodick, DW; Guerrero, M; Ikegami, D; Ito, H; Khanna, R; Kopruszinski, C; Moreira de Souza, LH; Moutal, A; Navratilova, E; Neugebauer, V; Patwardhan, A; Porreca, F; Roberts, E; Rosen, H; Vagnerova, B; Watanabe, M; Yamazaki, M; Yue, X, 2023) |
| "Paclitaxel-induced neuropathic pain (PINP) is a progressive and refractory side effect of chemotherapy with few effective treatments at present." | ( Gao, SJ; Li, DY; Liu, DQ; Mei, W; Song, FH; Sun, J; Wu, JY; Zhang, LQ; Zhou, YQ, 2022) |
| "Multiple sclerosis-associated central neuropathic pain (MS-CNP) is difficult to alleviate with clinically used pain-killers and so there is a large unmet medical need for novel treatments for alleviating MS-CNP." | ( Blanchfield, JT; Carpinelli de Jesus, M; Jones, A; Khan, N; Kong, D; Saqer, AA; Smith, MT; Williams, CM, 2022) |
| "The number of patients with diabetic neuropathic pain (DNP) continues to increase, but available treatments are limited." | ( Cao, H; Li, J; Li, X; Luo, GH; Wang, JW; Wei, N; Wu, SS; Ye, XY; Zhang, ZH, 2022) |
| "Since the treatment and management of neuropathic pain after spinal injury remains challenging, the potential therapeutic value of progesterone opens new traslational perspectives to prevent central pain." | ( Ferreyra, S; González, S, 2023) |
| "The management of the associated neuropathic pain remains difficult to treat." | ( Pickering, E; Rao, A; Steadman, KJ; Steels, EL; Vitetta, L, 2022) |
| "Current treatment approaches to manage neuropathic pain have a slow onset and their use is largely hampered by side-effects, thus there is a significant need for finding new medications." | ( Al-Khrasani, M; Essmat, N; Galambos, AR; Geda, O; Karádi, DÁ; Király, K; Lakatos, PP; Laufer, R; Szökő, É; Tábi, T; Zádori, ZS, 2022) |
| "Peripheral neuropathic pain induced by the chemotherapeutic cisplatin can persist for months to years after treatment." | ( Grace, PM; Heijnen, CJ; Junigan, JM; Kavelaars, A; Trinh, R; Zhang, J, 2022) |
| "Like other chronic neuropathic pain conditions, PPTTN can significantly alter the patient's quality of life, especially when pharmacological treatment is ineffective or not tolerated." | ( Capon, C; Crevant, A; Moreau, N; Pointin, A; Sulukdjian, A, 2022) |
| "Their neuropathic pain and quality of life were evaluated using the following questionnaires at diagnosis, after cisplatin therapy and after four weeks of TENS use: DN4, VAS scale, EORTC QLQ-C30 and FACT-L." | ( Dubljanin Raspopovic, E; Ilic, N; Jovanovic, D; Krstic, N; Mujovic, N; Nedeljkovic, U; Selakovic, I; Tomanovic Vujadinovic, S, 2022) |
| "Gelsemine relieves neuropathic pain by down-regulating DPP4 level in rats, providing a novel drug candidate and biomarker for neuropathic pain treatment." | ( Chen, J; Yang, L; Zhang, S; Zhou, G, 2023) |
| "The diagnosis and treatment of neuropathic pain is often clinically challenging, with many patients requiring treatments beyond oral medications." | ( Heller, JE; Miller, CJ; Nazarian, LN; Ng, A; Reeves, RA; Wang, D, 2022) |
| "US-guided percutaneous treatments for neuropathic pain present a growing opportunity for interprofessional collaboration between neurosurgery, clinicians who treat chronic pain, and sonologists." | ( Heller, JE; Miller, CJ; Nazarian, LN; Ng, A; Reeves, RA; Wang, D, 2022) |
| "Gabapentin can treat neuropathic pain syndromes and has increasingly been prescribed to treat nociplastic pain." | ( Bensen, GP; Collins, JE; Edwards, RR; Hunter, DJ; Katz, JN; Kostic, AM; Leifer, VP; Losina, E; Neogi, T; Paltiel, AD; Rogers, AC, 2023) |
| "Gabapentin can treat neuropathic pain syndromes and has increasingly been prescribed to treat nociplastic pain." | ( Bensen, GP; Collins, JE; Edwards, RR; Hunter, DJ; Katz, JN; Kostic, AM; Leifer, VP; Losina, E; Neogi, T; Paltiel, AD; Rogers, AC, 2023) |
| "Gabapentin can treat neuropathic pain syndromes and has increasingly been prescribed to treat nociplastic pain." | ( Bensen, GP; Collins, JE; Edwards, RR; Hunter, DJ; Katz, JN; Kostic, AM; Leifer, VP; Losina, E; Neogi, T; Paltiel, AD; Rogers, AC, 2023) |
| "Treatment of localized and superficial neuropathic pain caused by cancer was well tolerated and effective." | ( Chen, YY; Chiu, GL; Huang, YT; Lai, WS; Lin, PC; Liu, IT; Su, PF; Tsai, JH, 2023) |
| "Pregabalin is a drug used to treat neuropathic pain, and its use has increased substantially since 2007." | ( Cheik-Hussein, M; Cheng, ETL; Harris, IA; Lewin, AM; Lin, N; McAuley, JH, 2023) |
| "Chemotherapy-induced neuropathic pain (CINP) currently has limited effective treatment." | ( Ai, W; Guo, J; He, Y; Huang, X; Jiang, C; Kuang, H; Li, L; Li, N; Li, P; Liu, T; Sun, W; Sun, Y; Wang, Z; Wu, Y; Xiao, L; Xiong, D; Zeng, Q; Zhou, Q, 2023) |
| "Of 87 eligible cancer patients with neuropathic pain, 39 were recruited (47%), allocated to either the intervention (20 patients, virtual reality pain therapy software programme) or control (19 patients, viewing virtual reality videos)." | ( Bogdanovych, A; Chow, H; Chua, W; Chuan, A; Dai, E; Haider, S; Hatty, M; Lan, A; Shelley, M, 2023) |
| "The behavior of neuropathic pain was evaluated 2 h after drugs administration." | ( Bai, Y; Ji, L; Li, Y; Liu, X; Lu, B; Sun, W; Zhang, Q; Zhang, S; Zhang, Y; Zheng, H; Zhu, X, 2023) |
| "Chemotherapy-induced peripheral neuropathic pain (CIPNP) is an adverse effect observed in up to 80% of patients of cancer on treatment with cytostatic drugs including paclitaxel and oxaliplatin." | ( Aloi, VD; Luyten, K; Pinto, SJPC; Van Bree, R; Voets, T; Vriens, J, 2023) |
| "The treatment not only reduced neuropathic pain but also blocked CCI's effects on SCN9A upregulation and ERK phosphorylation." | ( Abbasi, Z; Baluchnejadmojarad, T; Farbin, M; Mehrabi, S; Roghani, M; Susanabadi, A, 2023) |
| "Clinically, neuropathic pain is a severe side effect of oxaliplatin chemotherapy, which usually leads to dose reduction or cessation of treatment." | ( He, XH; Li, YD; Liu, CC; Shen, KF; Wang, J; Wu, W; Xu, LJ, 2023) |
| "Treatment of neuropathic pain remains a challenge for modern medicine due to the insufficiently understood molecular mechanisms of its development and maintenance." | ( Ciapała, K; Ciechanowska, A; Mika, J; Pawlik, K; Rojewska, E, 2023) |
| "Chemotherapy-induced neuropathic pain (CIPN) describes a pathological pain state that occurs dose-dependently as a side effect and can limit or even impede an effective cancer therapy." | ( de Bruin, N; Geisslinger, G; Hahnefeld, L; Hausch, F; Heymann, T; Namendorf, C; Schmidt, MV; Schreiber, Y; Sisignano, M; Thomas, D; Uhr, M; Wedel, S, 2023) |
| "Diabetic neuropathic pain is one of the complications that affect a wide variety of the diabetic population and is often difficult to treat." | ( Almeida-Leite, CM; de Assis Ferreira, LC; de Castro Junior, CJ; de Lima, ME; Mariano, XM, 2023) |
| "The treatment of neuropathic pain is challenging due to its heterogeneous etiologies, lack of objective diagnostic tools and resistance to classical analgesic drugs." | ( Thouaye, M; Yalcin, I, 2023) |
| "Cancer chemotherapy-induced neuropathic pain is a devastating pain syndrome without effective therapies." | ( Ben-Salem, S; Bie, B; Borjini, N; Chen, J; Cheng, J; Dai, Y; Huang, P; Lin, F; Olman, M; Xu, J; Zhang, L, 2023) |